Inspiring future endocrinologists with a taste of SfE BES by Page, Nigel
THE MAGAZINE OF THE SOCIETY FOR ENDOCRINOLOGY
ISSUE 132 SUMMER 2019
ISSN 0965-1128 (PRINT)
ISSN 2045-6808 (ONLINE)
www.endocrinology.org/endocrinologist
SOCIETY GRANTS AND 
AWARDS 
It’s time to apply!
P3
TOMORROW’S 
ENDOCRINOLOGISTS 
Inspiring school students
P23
CELEBRATING 
EXCELLENCE 
Award winners for 2019
P22
The ATCG  
of  endocrinology  
from DNA  
to doctors…
Special features 
PAGES 6–19
P26–27
ENDOCRINE NETWORKS
Making connections
NEW GUIDE FOR NURSES
P29
Welcome support
2 | THE ENDOCRINOLOGIST | SUMMER 2019
WELCOME
Editor:
Dr Amir Sam (London)
Associate Editor: 
Dr Helen Simpson (London)
Editorial Board:
Dr Douglas Gibson (Edinburgh)
Dr Louise Hunter (Manchester) 
Dr Kim Jonas (London) 
Managing Editor: Eilidh McGregor
Sub-editor: Caroline Brewser
Design: Ian Atherton, Corbicula Design
Society for Endocrinology
Starling House 
1600 Bristol Parkway North
Bristol BS34 8YU, UK
Tel: 01454 642200
Email: info@endocrinology.org
Web: www.endocrinology.org
Company Limited by Guarantee
Registered in England No. 349408
Registered Oce as above
Registered Charity No. 266813
©2019 Society for Endocrinology
The views expressed by contributors
are not necessarily those of the Society.
The Society, Editorial Board and authors
cannot accept liability for any errors
or omissions.
OFFICERS
Prof GR Williams (President)
Prof E Davies (General Secretary)
Dr B McGowan (Treasurer)
Prof JHD Bassett (Programme Secretary)
COUNCIL MEMBERS
Prof R Andrew, Dr K Boelaert, 
Prof M Gurnell, Prof M Hewison, 
Prof GG Lavery, Dr DA Rees, 
Prof RM Reynolds, Prof JW Tomlinson
COMMITTEE CHAIRS
Clinical: Dr S Baldeweg
Corporate Liaison: Dr P Carroll
Finance: Dr B McGowan
Nominations: Prof GR Williams
Nurse: Mrs A Marland
Programme: Prof JHD Bassett
Public Engagement: Prof M Druce
Publications: Prof E Davies
Science: Prof CJ McCabe
Early Career Steering Group: Dr KE Lines
THE ENDOCRINOLOGIST ENQUIRIES
Please contact Eilidh McGregor
endocrinologist@endocrinology.org
ADVERTISING
Please contact
advertising@endocrinology.orgCONTENTS You can view this issue online:www.endocrinology.org/endocrinologist
P26–27
ENDOCRINE 
NETWORKS
Making connections
ON THE COVER…
P6–19
THE ATCG OF 
ENDOCRINOLOGY 
From DNA to  
doctors…
The Society welcomes news items, contributions, article suggestions and letters to the Editor. We would also like to hear your 
feedback on this issue of the magazine. 
Deadline for news items for the Autumn 2019 issue: 8 July 2019.
Become a contributor…  Contact the Editorial oce at endocrinologist@endocrinology.org
Front cover image ©Shutterstock
HEADLINES
3 Council and committee opportunities
Apply for grants and awards
Guidance and training
HOT TOPICS
4 The latest endocrine research
OPINION
21 Gene therapy: a new horizon
SOCIETY NEWS
22 
23
Society medal winners 2019,  
plus call for 2020 nominations
Getting a taste for endocrinology
NURSES’ NEWS
28
29 
Nurse sessions at SfE BES 2019
Welcoming Advanced Practice in 
Endocrine Nursing 
FEATURES
30 Remembering Saron Whitehead
AND FINALLY
31 Images by endocrinologists
A word from  
THE EDITOR…
Recently, whilst reviewing exam questions set for BSc Endocrinology students at Imperial College 
London, I was struck by the number that were related to the genetic basis of  endocrine disease. It is 
also striking how rapid the growth of  this area has been, with many of  these discoveries transpiring 
since I was a medical student myself, and I am not that old! 
The articles in this issue of  The Endocrinologist provide a valuable update of  this fast-moving field.
In this edition, Paul Brennan updates us on the ‘100,000 Genomes Project’ and Anna Gluck  
discusses the challenges of  researching rare genetic diseases. Soo-Mi Park highlights the benefits of  
running a multidisciplinary endocrine genetics clinic and Jennifer Prinn describes her experience 
of  familial genetic testing. William Drake and Morris Brown give an update on the genetic basis of  
primary aldosteronism. Daniel Osborn outlines hugely impactful recent advances in genome editing. 
Paul Newey addresses the issues of  ‘informed consent’ and ‘dealing with uncertain results’ with 
regards to genetic testing. Sadaf  Farooqi provides valuable insights into genetic factors influencing 
body weight and obesity, and Shivani Misra summarises important aspects of  genetic testing in 
diabetes mellitus. Kristien Boelaert provides an overview of  molecular markers in diagnosing thyroid 
cancer. Finally, Yalda Jamshidi looks to the future by presenting the latest developments in gene 
therapy.
I hope you enjoy reading this issue of  The Endocrinologist and have a warm and delightful summer.
With best wishes
AMIR SAM
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MAKE A DIFFERENCE  
TO YOUR SOCIETY
Help shape the future of  endocrinology by 
joining the Society’s Council or committees. 
31 July is the deadline to apply or nominate 
a colleague for one of  three vacancies on 
Council (starting November 2019).
13 September is the closing date for 
applications or nominations for places on the 
following Society committees (starting  
1 January 2020):
• Corporate Liaison
• Early Career Steering Group
• Nurse
• Programme
• Public Engagement
• Science
Full details are at www.endocrinology.
org/about-us/governance/council-
committee-nominations.
ENGAGE YOUR 
STUDENTS WITH 
ENDOCRINOLOGY
Apply for the Society’s Undergraduate 
Achievement Award to recognise and promote 
excellence in the study of  endocrinology. Your 
department could receive £300 per year, for  
3 years, to reward outstanding undergraduates 
for their endocrine-related studies. Applications 
close on 31 July 2019. Find out more at www.
endocrinology.org/grants-and-awards.
USE OF 
RADIOIODINE  
IN BENIGN 
THYROID 
DISEASE
Register now for the National 
Training Scheme for the Use of  
Radioiodine in Benign Thyroid 
Disease, which takes place in 
Birmingham on 27 June 2019. 
The course is essential for those 
seeking ARSAC (Administration 
of  Radioactive Substances 
Advisory Committee) 
certification for iodine-131 
administration in the treatment 
of  benign thyroid disease. 
Further details are at www.
endocrinology.org/events.
VACANCY FOR 
TREASURER
The Society’s Treasurer, Barbara McGowan, 
will complete her term of  office at the 2020 
AGM and a Treasurer-elect will be appointed 
at the 2019 AGM. Nominations may be made 
by Council or by any two Full Members of  
the Society by 5 July 2019. Find out more 
at www.endocrinology.org/about-us/
governance/council-committee-
nominations.
THE FUTURE OF 
ENDOCRINOLOGY AND 
DIABETES TRAINING 
The Society has worked with Association of  British Clinical 
Diabetologists to produce a joint position statement with 
recommendations for specialty training in endocrinology 
and diabetes. See www.endocrinology.org/clinical-
practice/society-position-statements.
HELP INSPIRE FUTURE 
ENDOCRINOLOGISTS
Apply for a Public Engagement Grant today! Funding is 
available for worksheets, factsheets or quizzes, short video 
clips or podcasts, or anything else you can think of. You 
could create learning resources for our You and Your 
Hormones website, or help schoolteachers and pupils learn 
about endocrinology. Visit www.endocrinology.org/
grants-and-awards/grants/public-engagement-
grant to find out more. Apply before 25 September 
2019.
27 June 2019 
NATIONAL TRAINING SCHEME 
FOR THE USE OF RADIOIODINE IN 
BENIGN THYROID DISEASE 
Birmingham, UK
11–13 November 2019 
SfE BES 2019 
Brighton, UK
15–17 November 2020 
SfE BES 2020 
Harrogate, UK
8–10 November 2021 
SfE BES 2021 
Glasgow, UK
www.endocrinology.org/events  
for full details
SOCIETY CALENDAR
www.endocrinology.org/grants-and-
awards for full details of all Society 
grants and prizes
GRANT AND PRIZE 
DEADLINES
SOCIETY  
SUPPORTED EVENTS
10 June 2019 
RET RESEARCH COLLABORATIVE 
NETWORK INAUGURAL MEETING 
London, UK
25–30 August 2019 
SPETSES SUMMER SCHOOL –  
NUCLEAR RECEPTORS, 
EPIGENOMICS, AND DISEASE 
Spetses, Greece
12 June 2019 
REGIONAL CLINICAL CASES 
MEETING GRANT
8 July 2019 
ENDOCRINE NURSE AWARD
8 July 2019 
MEDAL NOMINATIONS
31 July 2019 
UNDERGRADUATE ACHIEVEMENT 
AWARD
14 August 2019 
TRAVEL GRANTS
28 August 2019 
SfE BES REGISTRATION GRANTS
25 September 2019 
PUBLIC ENGAGEMENT GRANTS
30 October 2019 
PRACTICAL SKILLS GRANTS
20 November 2019 
EARLY CAREER GRANTS
20 November 2019 
EQUIPMENT GRANTS
20 November 2019 
ENDOCRINE NURSE GRANTS
OUR BEST ENDOCRINE ACADEMY YET!
Thank you to all who were involved in Endocrine Academy 2019 in Birmingham. The event was 
a sell-out success, and we hope all delegates enjoyed this popular, essential training and networking 
event. Don’t miss out: register early when next year’s dates are announced.
NEW ADVICE FOR ACUTE HYPOCALCAEMIA
An addendum updates the dose advice on the Society’s clinical guidance for emergency management 
of  acute hypocalcaemia in adults. You can read it at www.endocrinology.org/clinical-practice/
clinical-guidelines.
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HOT TOPICS
Society members have free access to the current  
content of Journal of Endocrinology, Journal of Molecular 
Endocrinology, Endocrine-Related Cancer and Clinical 
Endocrinology via the members’ area on the Society home 
page, www.endocrinology.org. Endocrine Connections and 
Endocrinology, Diabetes & Metabolism Case Reports, the 
Society-endorsed case reports publication, are open  
access and free to all.
SOCIETY FOR ENDOCRINOLOGY 
OFFICIAL JOURNALS 
HT
Inhibitors of apoptosis protect the ovarian reserve from 
cyclophosphamide
As we know one of  the successes of  modern medicine is that 2.5 million 
people now live with and beyond cancer. Cancer therapy may result in 
primary ovarian insufficiency in girls and premenopausal women. Loss 
of  ovarian follicles within the ovarian reserve leads to ovarian endocrine 
dysfunction and impaired fertility. 
Cyclophosphamide (CPA) is a gonadotoxic agent that destroys ovarian cells 
by crosslinking DNA. Luan et al. sought to precisely map the mechanism 
by which the ovarian reserve is depleted by CPA. They described how the 
active metabolite of  CPA, 1 μM 4-hydroxyperoxycyclophophamide (4-HC), 
specifically depletes primordial follicles without affecting primary and 
secondary follicles in three independent murine strains (CD-1, C57BL/6J 
and BALB/cJ) in vivo, and demonstrated that phospho-AKT (p-AKT) and 
cleaved PARP (cPARP) are present in primordial oocytes 3 days after CPA 
injection, consistent with the role of  these markers as part of  the apoptotic 
cascade. 
Additionally, treatment of  animals with specific inhibitors of  apoptotic 
pathway components, ETP46464 and CHK2, blocked 4-HC-induced 
DNA damage in vitro. These data suggest that CPA targets primordial germ 
cells in the ovarian reserve by stimulating apoptosis pathways. 
This is an exciting paper as it suggests that adjuvant therapies to protect 
primordial germ cells from the off-target effects of  CPA may reduce the  
risk of  POI, and brings hope for future fertility to many girls and  
women.
Read the full article in Journal of  Endocrinology 240 243–256
PEG10 is associated with treatment-induced neuroendocrine 
prostate cancer
It has been suggested that the placental gene PEG10 may have a role in the 
neuroendocrine (NE) differentiation of  advanced prostate adenocarcinoma 
following androgen receptor (AR) axis-directed therapy.
Kim et al. used a unique model of  enzalutamide resistance (ENZR) and 
neuroendocrine differentiation to study PEG10/AR interplay in enzalutamide 
treatment-resistant cell lines 42DENZR and 42FENZR compared with LNCaP  
and castration-resistant 16DCRPC cells.
ENZR cell lines with positive terminal neuroendocrine marker status  
displayed higher baseline expression of  PEG10 compared with LNCaP  
and 16DCRPC. Antagonism of  AR activity increased PEG10 expression,  
followed by an increase in terminal neuroendocrine markers. Conversely, 
stimulating R activity via androgen supplementation reversed PEG10  
and neuroendocrine marker expression in a time- and dose-dependent  
manner.
These results were supported by human data showing that PEG10 expression  
is highest in neuroendocrine prostate cancer (NEPC) and that an AR-dependent 
gene (for prostate-specific antigen) is negatively correlated with PEG10 in 
adenocarcinoma. Furthermore, ChIP assay confirmed binding of  activated  
AR to the PEG10 enhancer, decreasing PEG10 expression. 
While PEG10 did not drive NEPC, its knockdown reduced neuroendocrine 
markers in the cell lines. Moreover, PEG10 knockdown in vitro and in vivo 
attenuated tumour growth. Overall, these observations indicate that PEG10  
is an AR-repressed gene which modulates neuroendocrine markers in 
ENZR cells, and that targeting PEG10 in advanced prostate cancer with 
neuroendocrine features may yield therapeutic potential.
Read the full article in Journal of  Molecular Endocrinology 63 39–49
JOURNAL OF MOLECULAR ENDOCRINOLOGY
ERα regulates syndecan-1 in human breast cancer
Breast cancer is the primary cause of  cancer-related mortality among 
women. Patients who express the oestrogen receptor (ER), which mediates the 
tumorigenic effects of  oestrogens, respond to antihormonal therapy. Loss of  
ER expression or acquired resistance to oestradiol is associated with aggressive 
malignant phenotypes, which lead to relapse. These breast cancer subtypes 
overexpress syndecan-1 (SDC1), a transmembrane heparan sulfate proteoglycan 
that mediates angiogenesis, as well as the proliferation and invasiveness of  cancer 
cells.
Fleurot et al. have shown that activation of  ERα by oestrogens induces down-
regulation of  SDC1 expression in ER-positive MCF7 cells, but not in T47D 
cells. Loss of  ERα expression, induced by RNA interference or a selective ER 
down-regulator, led to subsequent SDC1 overexpression. Oestradiol-dependent 
down-regulation of  SDC1 expression required de novo protein synthesis, and was 
antagonised by treatment with BAY 11-7085, an irreversible inhibitor of  IκBα 
phosphorylation, which inhibits the activation of  NFκB. Down-regulation of  
SDC1 expression required ERα and activation of  IKK, but was independent 
of  downstream transcriptional regulators of  NFκB. BAY 11-7085 prevented 
oestradiol-mediated phosphorylation of  ERα on Ser118, increasing its 
proteasomal degradation, suggesting that IKK stabilised oestradiol-activated 
ERα, leading to subsequent down-regulation of  SDC1 expression.
Results showed that sustained ER signalling inhibits SDC1 expression. Such 
antagonism elucidates the inverse correlation between SDC1 and ER expression 
in ER-positive breast cancer, as well as the overexpression of  SDC1 in hormone 
receptor-negative breast cancer subtypes with the most aggressive phenotypes. 
These results identify SDC1 as an attractive therapeutic target for breast cancer, 
as well as for other endocrine-associated cancers.
Read the full article in Endocrine-Related Cancer doi:10.1530/ERC-18-0285
ENDOCRINE-RELATED CANCER
JOURNAL OF ENDOCRINOLOGY
©Shutterstock
Insulin entrains circadian rhythms with 
feeding times
In the field of  chronobiology, it has been  
understood for some time that food intake is  
an important timing cue (a ‘zeitgeber’) for the 
circadian clock. This has led to hypotheses about 
how the deleterious effects of  mistimed meals, 
or erratic eating patterns (during shift work, 
for example), might come about. However, the 
mechanism by which feeding entrains the clock  
has proved elusive.
Now, using mouse and in vitro studies, Crosby et 
al. have shown the importance of  insulin and the 
insulin signalling pathway for resetting the clock. 
Insulin signalling leads to the induction of  PERIOD 
proteins, which are an important component of  
the negative feedback loop of  the molecular clock. 
Interestingly, the suprachiasmatic nucleus of  the 
hypothalamus, which receives input from the 
retinohypothalamic tract and thus co-ordinates 
organismal rhythms with the light−darkness cycle, 
was found to be more resistant to the effects of  
insulin than peripheral tissues. For mice kept in 
constant darkness, however, delivery of  ‘mistimed’ 
insulin had significant enough effects on the clock 
to disrupt patterns of  activity onset, highlighting the 
importance of  insulin signalling as a zeitgeber.
Read the full article in Cell 177 896−909
ENDOCRINE HIGHLIGHTS
A summary of papers from around the endocrine community that have got you talking.
Hot Topics is written by Louise Hunter and Helen Simpson.
©123RF
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ENDOCRINE CONNECTIONS
CLINICAL ENDOCRINOLOGY
Hypertension in pregnancy due to DOC-secreting tumour
Marques and colleagues report an unusual cause of  hypertension detected in 
pregnancy. An incidental adrenal mass was detected during obstetric ultrasound 
in a woman with a history of  pre-eclampsia, hypertension requiring three agents, 
and also hypokalaemia. She did not have features of  Cushing’s syndrome and 
had aldosterone and renin levels that were low rather than high.
The patient was found to have grossly elevated levels of  11-deoxycorticosterone 
(DOC), a mineralocorticoid precursor. Magnetic resonance imaging 
demonstrated a 12-cm complex cystic adrenal mass. Treatment with 
antihypertensives (labetalol, doxazosin, diltiazem) continued until the post-
partum period, at which point the woman underwent surgical resection of  
what was found to be an adrenocortical neoplasm. Her hypertension and 
hypokalaemia resolved post-operatively.
The authors discuss the differential diagnosis of  a picture of  mineralocorticoid 
excess, as well as what is currently known about DOC-producing adrenal 
tumours.
Read the full article in Endocrinology, Diabetes & Metabolism Case Reports  
doi: 10.1530/EDM-18-0164
Adolescent use of combined hormonal contraception and peak 
bone mineral density 
This is an interesting meta-analysis suggesting that combined hormonal 
contraception (CHC) use in adolescents is associated with a lower peak bone 
mineral density (BMD) at the lumber spine if  used between ages 12 and 19. 
CHC use is common and is also used in young girls who have ovarian 
insufficiency of  any cause. We know that adolescence is a time for peak accrual 
of  bone density. Goshtasebi et al. performed a 12‐month LS meta‐analysis with 
eight paired comparisons in 1535 adolescents showed a weighted mean BMD 
difference of  −0.02 in CHC‐exposed adolescents (P=0.04) and the 24‐month 
LS meta-analysis with five paired comparisons in 885 adolescents showed a 
highly significant weighted mean BMD difference of  −0.02 in CHC‐exposed 
adolescents (P=0.0006). Adjustments for age and/or race, BMI and baseline 
BMD were made in four out of  nine studies. 
Not all studies described smoking, calcium intakes, alcohol consumption and 
exercise levels. This was not a randomised placebo-controlled trial, and describes 
an association; however, the data are highly statistically significant and we may 
need to pause for thought when considering CHC use in adolescents who have 
yet to accrue their peak bone mass.
Read the full article in Clinical Endocrinology 90 517–524
ENDOCRINOLOGY, DIABETES & METABOLISM CASE REPORTS
Are higher urinary cortisol levels associated with increased 
cardiovascular risk?
There are conflicting data on whether variations in physiological cortisol levels 
are associated with cardiovascular risk, and it can be difficult to compare results 
from previous studies because of  varying sample size, techniques for assessing 
cardiovascular risk and failure to adequately account for environmental factors. 
To address these issues, Haas et al. used a large sample size, selected the 
Framingham risk score to compute cardiovascular risk and performed the study 
in a highly controlled setting. They aimed to determine whether higher cortisol 
levels were associated with increased cardiovascular risk and whether caveolin-1 
(rs926198) risk allele carriers had increased cardiovascular risk.
This was a cross-sectional study of  574 non-diabetic individuals who completed 
a common protocol. Data collection included fasting blood samples, blood 
pressure measurements and 24-h urine free-cortisol collection. Of  these 
participants, 517 also completed caveolin-1 genotyping. Subjects were classified 
as belonging to either the low-mode or high-mode urine free-cortisol groups, 
based on the bimodal distribution of  urine free-cortisol.
In multivariate analysis, Framingham risk score was statistically higher in the 
high-mode cortisol group (10.22±0.43; mean±SEM) compared with the low-
mode cortisol group (7.73±0.34; P<0.001). Framingham risk score was also 
statistically higher in the caveolin-1 risk allele carriers (8.91±0.37) compared 
with caveolin-1 non-risk allele carriers (7.59±0.48; P=0.034). 
These data still do not prove causation and call into question any suggested 
intervention: should we be aiming to lower urine-free cortisol, or should we heed 
advice to watch our weight, BP and exercise? 
Read the full article in Endocrine Connections doi:10.1530/EC-19-0182
HT
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70,000 NHS patients would undergo WGS (people with cancer undergo 
WGS in their tumour DNA and their germ line, bringing the total number 
of  genomes to 100,000).
By 29 March 2019, when the project officially ended, over 100,000  
whole genomes had been sequenced in 85,000 NHS patients. At the  
time of  writing, this was the largest number of  genome sequences ever 
undertaken in a healthcare setting anywhere in the world.
PRACTICALITIES
People with rare inherited diseases were eligible for WGS if  they had 
specific disorders (see Table 1 for the eligible endocrine disorders) and had 
already undergone ‘standard’ genetic testing, if  available. Priority was given 
to multi-case families or ‘trios’ (affected child plus both unaffected parents). 
Consenting to WGS was not trivial: each participant was asked to sign a 
five-page form with several options relating to the extent of  analysis and  
use of  the sample for research (Table 2).
High quality germline DNA, extracted  
from blood, was shipped to a national biobank, 
then on to a purpose-built genome sequencing 
facility on the Wellcome Genome Campus in 
Hinxton (Cambridge, UK) for WGS, after which 
analysis was restricted to a panel of  carefully 
selected genes, driven by the reported phenotype, 
as well as optional ‘secondary findings’ gene 
panels. Gene panels were defined by a purpose-
designed open-access tool called PanelApp.1
People with most solid or haematological 
cancers were also eligible for WGS in both their 
tumour and their germ line. Here, however, the 
project hit two early problems. The first was 
formalin: this toxic chemical has been used for 
decades and, although it preserves tissue for 
histology, it also renders DNA unsuitable for 
WGS. Operating theatres across England faced 
(and many still face) the challenge of  removing 
formalin and sending tumour tissue fresh to 
pathology departments for selection of  tissue 
suitable for DNA extraction. Sounds easy, doesn’t 
it? It isn’t, believe me.
Haemato-oncologists also faced a challenge:  
we usually use blood samples to extract germline 
DNA for WGS, but what if  the patient has 
leukaemia? Alternative sources of  germline  
I have seen the future. It consists of six billion 
nucleotides (a tiny bit less if you’re genetically 
male). Whole genome sequencing (WGS), once a 
‘holy grail’, will be routine for many NHS patients 
in England from 2019.
In a recent clinic, I met an old friend called Robert. I’ve seen him on  
and off for a decade since he was transferred to me by a colleague who  
had made a clinical diagnosis of  Shprintzen–Goldberg syndrome (SGS)  
in the days before genetic testing was possible. SGS is a rare genetic 
condition that shares some features with Marfan syndrome but, in 
particular, includes a relatively small head and mild learning problems. 
Mutations in the SKI gene were first described in people with SGS in 2012, 
although Robert’s SKI genes were tested and found to be normal. Robert 
lived without a diagnosis until 2pm on 13 March 2019, when I was able  
to end 31 years of  diagnostic uncertainty.
How? He and his parents had taken part in the 100,000 Genomes  
Project. We were able to analyse far more genes than previously  
possible and there was the answer: Robert is a compound heterozygote  
for two different mutations in a gene called ASPM. He has autosomal 
recessive primary microcephaly type 5. End of  story. Or is it? 
POLITICS AND AMBITION
The 100,000 Genomes Project in England was the brainchild of   
politicians determined to make the NHS in England the first healthcare 
service in the world to use WGS as a routine first-line diagnostic test for 
people with undiagnosed rare diseases and individuals with cancer. The 
scale of  the ambition was staggering: over a period of  4 years or so,  
FEATURE
WRITTEN BY PAUL BRENNAN
THE 100,000 GENOMES
PROJECT  
GENETICS
‘…when the project officially ended, 
over 100,000 whole genomes had been 
sequenced in 85,000 NHS patients … the 
largest number of genome sequences ever 
in a healthcare setting anywhere in the 
world.’
Table 1. 100,000 Genomes Project: eligible rare endocrine disease diagnoses
• Congenital adrenal hyperplasia
• Familial/sporadic hypoparathyroidism
• Disorders of sex development
• Early-onset familial ovarian failure
• Unexplained intrauterine growth restriction
• Idiopathic hypogonadotrophic hypogonadism
• Early-onset severe syndromic or non-syndromic obesity
• Familial early-onset non-insulin-dependent diabetes
• Hyperinsulinism 
• Neonatal diabetes
• Diabetes with additional phenotypes suggestive of a monogenic aetiology
• Insulin resistance (including lipodystrophy)
• Multi-organ autoimmune diabetes
• Congenital hypothyroidism
• Resistance to thyroid hormone
• Multiple endocrine tumours
• Phaeochromocytoma/paraganglioma
• Parathyroid carcinoma
• Familial non-medullary thyroid cancer
See www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project 
for a list of all of the eligible diseases.
 THE ENDOCRINOLOGIST | SUMMER 2019 | 7
UNCERTAINTY
One particular challenge is a term you will all need 
to familiarise yourselves with: ‘variants of  uncertain 
significance’ (VUS or VOUS). At present, our 
understanding of  the genome is relatively basic. 
We simply haven’t got to grips with the full extent 
of  normal genome sequence variation. It’s a bit like 
the biggest challenge at medical school: to learn 
what is normal. It is not uncommon – at present 
– for DNA sequencing to identify a variant in our 
DNA that cannot be classified as either ‘normal’ or 
‘pathogenic’ (the term ‘mutation’ is falling out of  
use4). We can expect VUSs to be commonplace for 
many decades to come, and we will see the rapid 
development of  ‘genomics multidisciplinary teams’ 
in the NHS to support clinicians faced with a VUS.
One thing has become clear already: accurate, complete phenotyping is 
vital when it comes to interpreting VUSs. It turns out that diagnostic skills 
are just as important in the genomic era as ever before.
THE FUTURE
This year, the NHS in England will launch the NHS Genomic Medicine 
Service. Existing DNA diagnostics provision is being reorganised to create 
seven Genomic Laboratory Hubs, supported by seven Genomic Medicine 
Centres, providing comprehensive DNA analysis for both rare diseases and 
cancer. For the first time, clinicians across the NHS will have direct access 
to tests – including WGS for some diseases – which may for years have been 
the sole domain of  clinical genetics services. This will not be a single event, 
but a process that will take time. 
We are Generation Genome.5 Genomics is no longer locked in its ivory 
tower. Let’s work together to realise its full potential for our patients. It’s 
a big challenge, for sure, but we’re the first health service in the human 
universe to do it at such scale and pace, so let’s get it right. 
PAUL BRENNAN
Consultant in Clinical Genetics, Newcastle Hospitals NHS Foundation 
Trust, Newcastle upon Tyne
FEATUREGENETICS
DNA are needed: skin biopsies, fluorescence-activated cell sorter-enriched 
non-tumour leucocytes or saliva, for example. This challenge is still being 
addressed, but it will be solved.
OUTCOMES
At present, the routine 100,000 Genomes Project data pipeline effectively 
asks ‘is there a variant of  interest in these specific genes?’. This is not the 
same as whole genome analysis, in which the question is ‘is there a variant 
of  interest in this entire genome?’ Cancer data analysis is more complex 
and requires a broader approach to detect large and small scale genomic 
rearrangements. Using these current approaches, just over 20% of  patients 
with rare diseases get a diagnosis (on average: the hit-rate is higher for some 
disorders and lower for others). A greater proportion of  cancer patients are 
found to have a clinically actionable variant that links to a therapy or trial 
opportunity.
The challenge of  data analysis on this scale is truly staggering and, although 
this ‘first-pass’ analysis might seem relatively restricted, we can expect wider 
analyses as the data are re-examined periodically as part of  the legacy 
activities of  the 100,000 Genomes Project.2
Further analysis of  genome data can also be undertaken by researchers 
working as part of  disease-specific GeCIPs (Genomics Clinical 
Interpretation Partnerships), for example the Endocrine and Metabolism 
GeCIP.3 These are groups of  interested clinicians and academics who have 
agreed to collaborate on specific projects using the clinical and genome data 
resource compiled during the 100,000 Genomes Project.
Throughout 2019 we will see the return of  thousands of  results from 
Genomics England to the NHS Genomic Medicine Centres. Many centres 
have already developed a great deal of  experience in validating such results 
and providing clinicians with clinical-grade reports for their clinics.
‘We are Generation Genome.’
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Table 2. Consent options for whole genome sequencing (WGS)
• Collection and use of samples for WGS
• Collection and use of health data 
• Analysis of genes relevant to the patient’s disease (defined by PanelApp1)
• Analysis of genes associated with ‘secondary findings’ (genes which may cause 
serious or life-threatening diseases e.g. BRCA1/2, Lynch syndrome, familial 
hypercholesterolaemia; these now also include pharmacogenomics variants that may 
predict adverse response to drugs)
• Analysis of genes associated with ‘reproductive findings’ (carrier status for serious 
or life-threatening autosomal recessive or X-linked disorders that might aect the 
participant’s child(ren) e.g. cystic fibrosis) 
• Access to genome and clinical data by researchers and/or commercial companies
©Shutterstock
‘…accurate, complete phenotyping is 
vital when it comes to interpreting VUSs. 
It turns out that diagnostic skills are just 
as important in the genomic era as ever 
before.’
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A more modern approach is to use large scale sequencing databases that 
link genetic variants to phenotype data (such as the UK Biobank). However, 
genome-wide association studies (GWAS) have limitations for rare diseases, 
because screening thousands of  genes in very few patients is likely to yield 
false-positive results. To obtain statistical power, GWAS rely on large sample 
sizes, which are only available for common diseases. Additionally, these 
databases are often retrospective observations rather than prospective studies, 
which means that data and diagnosis can be missing and/or unreliable, and 
family history is often not available.
OPPORTUNITIES FOR TREATMENT
Despite these challenges, there have been success stories with direct patient 
benefit. One of  the big opportunities for the treatment of  rare diseases is 
drug repurposing, which is a lot more cost-effective than developing a drug 
from scratch. In some cases, existing indications can be extended to rare 
diseases. For example, our research group identified a novel GNA11 mutation 
in a patient with familial hypocalciuric hypercalcaemia type 2 and showed 
impairment of  the calcium-sensing-receptor (CaSR) signalling pathway in 
vitro. In collaboration with Helsinki University Hospital, Finland, the patient 
was treated with cinacalcet, a positive allosteric modulator of  CaSR, which 
is approved for the treatment of  secondary hyperparathyroidism, caused by 
end-stage renal disease. As a result, the patient became normocalcaemic.
Another interesting approach is to make use of  the many compounds that 
have been shown to be safe for use in humans, but failed in clinical trials 
because they were not effective enough for the indication for which they 
were tested. For example, the calcilytic ronacaleret failed in a phase II study 
because of  lack of  efficacy in postmenopausal women with osteoporosis. It 
has recently been shown to rectify impaired glucose tolerance in a mouse 
model for inherited hyperglycaemia, making it a potential candidate for the 
treatment of  genetic forms of  diabetes.
Gene therapy is currently a last resort treatment for certain cancer types. 
Looking to the future, it is certainly a promising therapeutic approach for 
genetic diseases. However, germline mutations occur in every single cell of  
our body and targeting therapies to specific tissues will be a challenge.
In conclusion, researching rare diseases is crucial for millions of  patients 
worldwide. Without the incentives for pharmaceutical companies to 
investigate treatments, it falls mainly to universities and research labs to 
identify the genetic mutations responsible, and to propose new treatments. 
This not only benefits the patients, but also advances our understanding of  
the underlying biology. Moreover, with an increasing number of  companies 
offering DNA self-testing, we need to educate and inform the public about 
the work we do to differentiate between benign polymorphisms and disease-
causing mutations.
ANNA GLUCK
PhD Student, Oxford Centre for Diabetes, Endocrinology and 
Metabolism, Radclie Department of Medicine, University of Oxford
As a young researcher, I find studying rare genetic 
conditions both rewarding and challenging. In the 
EU, a disease is defined as rare if it aects fewer 
than one in 2000 people,1 with the majority of 
cases thought to be of genetic origin.
The most prevalent monogenetic disorder is cystic fibrosis. It is caused by 
a mutation in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene and affects mainly the lungs, but also other organs, such as the 
pancreas, liver, kidneys and intestines. The condition affects one in 3000 
newborns,2 which equates to 226 new patients in England and Wales every 
year.3 This life-threatening condition is common enough and severe enough 
for many countries to have implemented screening in maternity wards.
Most conditions, however, are much rarer than that. Personally, I work on 
disorders related to calcium homeostasis, and here prevalence as low as one 
in 13,000 individuals4 has been reported.
THE RESEARCH CONUNDRUM
Even though the individual conditions are rare, the chance of  having a rare 
disease is nevertheless quite high. According to estimates by the National 
Institutes for Health Research (NIHR), rare diseases could affect as many 
as 10% of  the population. Here, we have a conundrum: on the one hand, 
we want to help the millions of  patients living with these rare conditions; 
on the other hand, it is not lucrative for funding bodies and pharmaceutical 
companies to invest resources in this area, because the cost of  developing a 
treatment for a rare disease is no cheaper than for a prevalent one.
This problem has partly been addressed by the Orphan Drug Act 1983, 
offering financial and regulatory incentives to companies developing and 
selling such treatments. However, the return on investment will still be  
much lower than for common conditions.
UNDERSTANDING THE UNDERLYING BIOLOGY
Even where there is the incentive to find novel treatments, we first need to 
understand the underlying biology. The publication of  the human genome 
in 2003 transformed the field of  genetic research. However, investigation 
of  rare genetic diseases has proved especially difficult. Traditionally, it is 
based on family studies. In theory, the recipe is simple: take a kindred with 
an inherited disease, identify mutations that are unique to affected family 
members as opposed to unaffected ones and show that there is a functional 
change in a suitable in vitro system.
In practice, this requires access to an entire family’s medical history and 
patient samples, which in the modern world often involves co-ordination 
between several hospitals in different parts of  the country. Within any single 
family, thousands of  genetic mutations are shared. Even when comparing 
multiple affected versus unaffected family members, we still find ourselves 
with dozens (or if  we are unlucky, hundreds) of  candidate genes, each 
of  which has to be painstakingly tested. We therefore normally require a 
large number of  patients from multiple families for the study. With a rare 
condition, it can be impossible to obtain sufficient samples to achieve a 
scientifically rigorous conclusion.
FEATURE
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THE CHALLENGES OF RESEARCHING 
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(VUS), usually a novel missense variant in a gene where the pathogenic 
changes are commonly loss-of-function variants. Interpretation of  such 
variants requires expertise and additional training.
Once a genetic diagnosis is confirmed, most affected individuals are 
naturally concerned and anxious about the risk to their immediate family 
and seek advice about risk to their relatives, their future children and how 
to access genetic testing and screening for disorders. Those of  reproductive 
age do not wish to pass on their disorder to their children and therefore seek 
information about the options available.
MULTIDISCIPLINARY CLINICS
A joint clinic with a clinical geneticist appears sensible, in which the 
expertise of  both specialties can be harnessed for optimum patient 
management. Clinical genetics services in the UK are offered regionally 
in a ‘hub and spoke’ model. Specialist genetics multidisciplinary clinics 
are often held in regional tertiary teaching hospitals, which draw patients 
from the whole region served and often quite a way beyond, depending 
on the geography covered by the referring specialist service, e.g. head and 
neck paragangliomas referred by a national skull base surgical service. It 
is standard practice for a clinical geneticist to draw up a family history 
covering three to four generations. This can be useful for:
• providing detailed information about affected members
• seeking confirmation of  the disorder and obtaining a mutation report if  
available
• identifying the presence of  any consanguinity
• identifying at-risk relatives
• determining the likely inheritance pattern
• ensuring that confidentiality is strictly observed between members 
of  the same extended family, except where specific consent to share 
information is obtained.
The geneticist can inform the patient about the diagnosis or diagnoses in 
consideration, their inheritance pattern(s) and therefore the potential risks to 
their relatives, the implications of  having a diagnostic or a predictive genetic 
test, and the implications for insurance policies of  the latter test, and also 
advise when childhood predictive testing is appropriate. 
Various reproductive options can also be discussed for couples where any 
future children are at high risk. These include:
• non-invasive prenatal diagnosis for paternally inherited autosomal 
dominant disorders or autosomal recessive disorders where the couple 
are confirmed carriers, or sexing for X-linked disorders
• invasive prenatal diagnosis by chorionic villus sampling or 
amniocentesis
• pre-implantation genetic diagnosis for disorders approved by the 
Human Fertilisation and Embryology Authority (www.hfea.gov.uk).
The genetic test is then arranged after written consent is obtained, where 
the option of  sharing their results with family members is included as an 
integral part (so that future cascade family testing can take place smoothly 
without breaking confidentiality). The possibility of  unexpected results, 
including a VUS, is discussed in the consent process, as well as anonymous 
use of  the test results to improve healthcare within the NHS (useful for 
valuable NHS audit projects). If  a genetic disorder is confirmed, then the 
genetics service is well accustomed to facilitating family cascade testing with 
the generation of  an open ‘To Whom It May Concern’ letter that can be 
passed to the at-risk family members, thereby assisting with GP referrals for 
these relatives.
THE FUTURE
The challenge with genetic tests now mainly lies in interpretation of  the 
results and any variants that are detected. Life would certainly be easier 
FEATUREGENETICS
The era of genomic medicine has been transforming 
the clinical care of patients in mainstream medicine. 
Next generation sequencing (NGS) on whole exome 
platforms is soon to be phased into whole genome 
platforms, now that the piloting of the 100,000 
Genomes Project (www.genomicsengland.co.uk) is 
coming to an end. It has enabled more accessible 
genetic tests than ever.
The genetic testing landscape has changed dramatically in the last decade: 
from single gene tests, moving on to panel gene tests and recently on to 
agnostic trio whole exome, and now genome, sequencing. This is a time of  
unprecedented increase in knowledge of  the genetic basis of  disease against 
a background of  rapidly changing technology, and has been translated 
into the highest diagnostic rate for hereditary disorders in medical history. 
It is therefore not surprising that there is an increasing demand for, and 
expectation of, genetic services.
Many patients seen in endocrinology and diabetes clinics are at risk of  
having a monogenic basis to their disorder, from rare neuroendocrine 
tumours such as phaeochromocytomas and paragangliomas, and 
multiglandular disease, to the more common disorder of  primary 
hyperparathyroidism. Maturity-onset diabetes of  the young (MODY) 
and mitochondrial diabetes are also considerations in those with familial 
diabetes. The practising endocrinologist therefore needs to carefully 
consider whether a genetic basis is worth exploring by taking a careful 
family history in the first instance. Diagnosing a hereditary disorder not 
only benefits the patient, but also their wider family.
KEY QUESTIONS
Endocrinologists may be knowledgeable about many of  the familial 
endocrine disorders (after all, they are the ‘bread and butter’ of  MRCP 
exams!). However, most endocrinologists may not be familiar with arranging 
genetic tests, interpreting the reported variants, the need to arrange cascade 
family screening, providing advice about recurrence risk and reproductive 
options. Key questions are:
• Is the test a diagnostic test?
• Is it a predictive test where there is a known familial disorder and a 
known familial pathogenic variant?
• Are they seeking a predictive test in a child for an adult-onset disorder, 
for which there are clear guidelines from the British Society for Genetic 
Medicine (www.bsgm.org.uk)?
• Are they seeking a carrier test for an autosomal recessive disorder or an 
X-linked disorder?
• Are they familiar with the availability of  single genes and multiple gene 
panels (by disorder or an all-encompassing inherited cancer exome 
panel)?
• Are they aware of  the limitations of  NGS tests, such as poor 
optimisation for the detection of  dosage changes (small deletions or 
duplications), and therefore the need to request additional tests such as 
multiplex ligation-dependent probe amplification (MLPA) analysis?
• Do they know of  the timescale for results (on average, 4 months for 
NGS panel testing, 2 months for single gene testing, 2–4 weeks for 
predictive genetic testing, 1–2 weeks for urgent prenatal testing)?
• Are they experienced in obtaining formal written consent (standard 
forms are available from genetics services) for genetic testing, which 
covers aspects such as sharing results with the rest of  the family and 
preparing the patient for the possibility of  unexpected results? This 
includes the possibility of  finding a variant of  uncertain significance 
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provision through commissioning seven Genomic Central Laboratory  
Hubs working in conjunction with the clinical genetics services, capitalising 
and building on the output of  the 100,000 Genomes Project. This will  
allow access to the widest range of  genetic tests to date. One of  the main 
aims of  this change is to embed genomics into mainstream medicine. 
Therefore, all NHS specialists will have access to, and are expected to use, 
genomic testing before the end of  the year, on whole genome platforms 
where all requests are funded centrally, provided that the testing criteria 
are met. The requests are placed centrally but testing will be directed to 
the laboratory assigned to perform the relevant test. Therefore, the time 
has come for the endocrinologist to become genomics savvy, and a close 
working relationship with their local clinical geneticists becomes more 
pertinent than ever.
SOO-MI PARK
Consultant in Medical Genetics, Addenbrooke’s Treatment  
Centre, Cambridge University Hospitals NHS Foundation Trust
for all practising clinicians who regularly request genetic tests if  we had 
long-established and detailed databases of  both pathogenic variants for 
known disorders and variants present in the general population presumed 
to be harmless or of  low penetrance. Databases for both do exist (ClinVar, 
www.ncbi.nlm.nih.gov/clinvar; HGMD, www.hgmd.cf.ac.uk; 
DECIPHER, https://decipher.sanger.ac.uk; gnomAD, https://
gnomad.broadinstitute.org) and can prove helpful in many cases, but 
more information still needs to be gathered and compiled for this process to 
be facilitated. The UK has led the world on nationally co-ordinated whole 
exome and genome sequencing research studies (e.g. DDD study, https://
decipher.sanger.ac.uk/ddd, and the 100,000 Genomes Project) 
through our integrated NHS services, and results from these studies are 
generating much-needed information for the genomic databases, which will 
help ease the burden of  interpreting variants in the future. 
NHS England, through its NHS Genomic Medicine Service initiative 
(www.england.nhs.uk/genomics/nhs-genomic-med-service), 
has recently brought about reconfiguration of  genetics laboratory service 
FEATURE GENETICS
of  course, this is the right age for this to occur. Then the MEN anxiety 
kicked in. What if  it wasn’t growing pains? What if  he had high calcium 
levels, and the pins and needles he was experiencing were a result of  
hyperparathyroidism? Or worse, had he developed brown tumours from 
exposure to high calcium for such a long time? After a long battle with 
my GP, who didn’t really understand why I was concerned (calcium levels 
aren’t routinely tested), they finally agreed to test my son’s calcium levels. 
Fortunately, all was fine. But, there was still this nagging doubt in my mind. 
How did I know that he didn’t have MEN or wasn’t going to suffer the same 
experiences as me growing up?
THE TESTING
Luckily, I had a consultant at King’s College London who was very 
supportive and referred me and my husband to the genetics department 
at Guy’s and St Thomas’ Hospital in London. We were offered a further 
session of  genetic counselling, and were required to talk about our reasons 
for wanting the children tested at such young ages (they were aged 5 years 
and 18 months at the time). Generally, testing for MEN occurs around  
10 years of  age, as symptoms don’t tend to show before then. We explained 
that that I would feel much better if  I knew whether the symptoms they 
were displaying were ‘normal’ childhood symptoms or MEN symptoms.  
If  the genetics came back negative for MEN, then I could assume that the 
risk of  anything being MEN-related was much reduced.
The appointment was long and the kids played up because they were bored. 
Then came the actual blood tests. The baby was easy, she sat on her dad’s 
lap and didn’t blink a eye. My son, however, being 5 at the time, decided 
that he didn’t want a strange person sticking a needle in his hand. However, 
after a few minutes (which felt like hours), he reluctantly agreed. I think that 
testing at such a young age is valuable, as children don’t remember having 
the blood test, and, if  negative, they don’t even need to know that they 
underwent a test. If  positive, it gives them a good standing for the coming 
years, which will be full of  blood tests and scans.
Jennifer Prinn considers her family’s experience 
of genetic testing, and whether she would advise 
other families in similar situations to get tested.
Is genetic testing a good thing or a bad thing? For our family, I would say it 
has been a benefit. Let me explain why…
In 2012, I was diagnosed with multiple endocrine neoplasia (MEN) 
type 1, after breaking my knee in 2010 and then finally undergoing 
a parathyroidectomy in 2011. When we discovered I had this genetic 
condition we decided, because the gene is dominant, that we wouldn’t 
have any more children. How wrong we were! Three months after my 
parathyroid operation, I fell pregnant (after 12 years of  infertility and two 
previous cycles of  IVF!).
While I was pregnant with my second child (my first had been born via IVF 
back in 2007), I underwent genetic counselling and testing. The counselling 
involved discussions with a geneticist, my consultant and a nurse specialist. I 
was also offered the opportunity to have access to a counsellor.
THE ANXIETY
For me, knowing I had a genetic condition that had been passed down 
was difficult to understand. My mum passed away when I was young, 
presumably from a MEN-related condition, and here I was, with two 
children, to whom I could have passed the condition. The genetics 
appointment was simple, it was the wait for the results that took time as 
it took almost 6 months. Despite this, I would advocate genetic testing for 
anyone who has a strong possibility of  MEN.
When my son complained of  recurring pins and needles, I initially thought 
that this was down to growing pains. He was nearly 6 years old and, 
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didn’t quite understand the huge relief  that these results carried, but they 
knew how important it was to me.
WAS IT WORTH IT?
So, let’s talk genetic testing. Is it worth it? For parental reassurance, where 
there is a high risk of  transmission, then I would say 100%. You can find 
out whether your child has a predisposition to a disease and you can 
prepare yourself  for all that comes with the diagnosis. Some of  us are 
lucky, our journey with genetics stops with us, but that doesn’t stop us being 
grateful for the opportunity we had.
JENNIFER PRINN 
RegPharmTech, Retired Pharmacy Technician, MEN1 patient
FEATUREGENETICS
THE RESULTS
The wait was agonising. Every time the phone rang I was expecting the 
bad news that the results were in. Two weeks before Christmas in 2012 
the results came back – both kids were free from the same MEN gene that 
I carry. I cried, my husband cried and the girls in my office cried. Many 
‘So, let’s talk genetic testing. Is it worth 
it? For parental reassurance, where there 
is a high risk of transmission, then I 
would say 100%.’
Positron emission tomography–computed tomography (PET-CT) scanning 
has the potential to expand capacity for investigation. The most advanced 
PET tracer is metomidate, a methyl analogue of  the anaesthetic agent 
etomidate. A large, prospective study, MATCH, comparing 11C-metomidate 
PET-CT with AVS, will report in 2020. Alternative 18F tracers are in 
development, making PET available nationally.
GROWTHS AND GENETICS
Knowledge of  the aetiopathogenesis of  PA has blossomed during the past 
decade and is an important ‘driver’ of  renewed interest and advances in 
practice. Most aldosterone-producing adenomas (APAs) harbour a somatic 
mutation of  an ion channel or transporter. First recognised were mutations 
in the KCNJ5 gene, a potassium channel that helps maintain cell membrane 
hyperpolarisation. Loss of  selectivity for potassium results in sodium influx 
and cell membrane depolarisation, inward movement of  calcium and 
activation of  aldosterone synthesis and secretion. KCNJ5 mutations are by 
far the commonest in classical Conn’s adenomas of  younger women.4 But 
their discovery revealed the paradox that these adenomas resemble cortisol-
producing, rather than aldosterone-producing, cells of  normal adrenal, and 
indeed secrete more cortisol than aldosterone. Even if  their cortisol secretion
is clinically insignificant, it can confound the aldosterone/cortisol ratio at AVS.
The paradox was resolved by the discovery of  commoner but smaller APAs 
with somatic mutations in sodium or calcium ATPases (ATP1A1, ATP2B3) 
or calcium channels (CACNA1D and CACNA1H). These APAs resemble 
physiological aldosterone-producing cells, and typically elude diagnosis – at 
least until the onset of  resistant hypertension. Their hallmark mutations, and 
development of  PET ligands and specific antisera for aldosterone synthase, 
PREVALENCE AND PENALTY
Prospective studies indicate that 8–13% of  unselected hypertensive patients 
have PA, of  whom only a minority have hypokalaemia.1 Meta-analysis shows 
that the cardiometabolic penalty of  PA (stroke, atrial fibrillation, ischaemic 
heart disease) exceeds that of  essential hypertension by at least 2:1.2 These 
data should trigger a ‘call to arms’ for development of  screening strategies 
to detect PA, to reverse (medically or surgically) the excess morbidity. The 
reality is sobering; fewer than 1% of  cases of  PA are detected and treated.
DETECTION AND DIAGNOSIS
No ‘real-world’ case-finding protocols (other than measuring renin  
and aldosterone in all hypertensive patients) are available. Endocrine 
Society guidelines acknowledge their inappropriateness for primary care. 
A recent large trial, PATHWAY-2, indicated major benefits from the 
addition of  spironolactone in patients with resistant hypertension. This 
study supports the high prevalence of  PA, and may add weight to calls for 
spironolactone to be considered earlier than step 4 in the treatment  
of  hypertension.
LOCALISATION AND LATERALISATION
Even at current diagnosis rates for PA, invasive investigation by adrenal 
vein sampling (AVS) is a major ‘bottleneck’. Only a handful of  centres are 
able to reliably cannulate both veins – and both the end (to find unilateral 
PA) and the means (measurement of  aldosterone/cortisol ratio) may be 
outdated. Fewer than half  the patients with unilateral PA are cured by 
adrenalectomy. When 1% of  the population has PA, precision medicine is 
required to ensure that expensive procedures lead to years of  drug-free cure 
in a high proportion of  those selected.3
WRITTEN BY WILLIAM DRAKE AND MORRIS BROWN
KEEPING UP WITH THE GENES
IN PRIMARY ALDOSTERONISM  
Primary aldosteronism (PA or Conn’s syndrome) was previously considered a ‘niche’ area of 
endocrinology, limited to patients with hypertension and hypokalaemia. Clinical and molecular 
discoveries have propelled it into the limelight, as one of the most exciting, fast-moving areas of 
endocrine practice.
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safety and feasibility study of  endoscopic, transgastric RFA of  left-sided 
APAs (FABULAS) is currently recruiting.
CONCEPTS AND CONCLUSIONS
The PA landscape has transformed since Jerome Conn’s original description 
in 1954,9 and long held assumptions may shortly appear naïve or over-
simplistic. Is the distinction between unilateral and bilateral PA truly binary? 
Do we ‘cure’ patients by surgery or merely ‘debulk’ their disease? For anyone 
with a developing clinical and/or academic interest in PA – your timing is 
impeccable.
WILLIAM DRAKE
Professor of Clinical Endocrinology, Barts and the London School of 
Medicine
MORRIS BROWN
Professor of Endocrine Hypertension, Barts and the London School 
of Medicine
permitted recognition of  an inverse correlation between enzyme density and 
size of  APA.5 No nodule on CT/magnetic resonance imaging is too small 
to be an APA. Indeed, the most common sites of  autonomous aldosterone 
production are microscopic aldosterone-producing cell clusters, 60% of  
which have similar mutations of  CACNA1D to those found in APAs.6 More 
than 40 activating mutations are now described, all in/near the Ca2+ pores. 
Investigational inhibitors of  Cav1.3, encoded by CACNA1D, completely 
suppress aldosterone secretion by adrenocortical cells, and could become the 
precision medicine for PA. 
None of  the ion channel mutations is implicated in tumour formation, nor 
predicts higher cure rates. However, co-existence of  cortisol and aldosterone 
synthesis leads to secretion of  unusual hybrid steroids, whose measurement 
as a biomarker for solitary APAs with KCNJ5 mutation may become a 
valuable diagnostic and prognostic tool.7 Alternatively, somatic mutations 
are now being found in non-ion channel genes previously associated with 
tumour formation, and these may identify a subset of  patients with sustained 
clinical cure after removal of  the APA. For example, CTNNB1 mutations 
are found in ~5% of  APAs, which allow activated β-catenin to enter the 
nucleus and re-direct cell differentiation towards its adrenogonadal origin.8 
The consequent high expression of  luteinising hormone/human chorionic 
gonadotrophin receptors leads to explosive onset of  PA in early pregnancy or 
menopause. Removal of  the APA achieves sustained clinical cure, attributed 
to the briefness of  vascular exposure to high aldosterone levels.
RESECTION AND REDUCTION
Laparoscopic adrenalectomy is the mainstay of  non-medical treatment 
for PA, but several factors contribute towards caution in recommending 
surgery: limited NHS capacity, uncertain clinical outcome, and the 1960s 
timewarp of  resecting a whole organ as treatment for a 1-cm, benign lesion. 
Radiofrequency ablation (RFA) of  APAs is a developing alternative. A UK 
FEATURE GENETICS
joining them together using DNA ligase IV.3 In the majority of  cases, the 
correct ends rejoin. However, annealing incorrect ends or the removal of  
damaged nucleotides can lead to chromosomal aberrations and mutations.4 
Hence, NHEJ is error prone, a characteristic researchers exploit to disrupt 
gene function. 
Conversely, HDR uses an intact copy of  the gene loci to repair the  
broken sequence, an accurate but slow method.2 After a DNA break 
event, pathways are activated to remove damaged nucleotides by nibbling 
forward and reverse DNA strands, leaving single-stranded DNA overhangs.5 
Subsequently, the DNA ends are coated with recombinases and co-factors, 
RESTORING DNA BREAKS
A number of  different methods exist to cause genomic cuts; however, repair 
mechanisms remain the same. DNA breaks can occur naturally through 
intracellular nucleases/reactive oxygen species or externally by ionising 
radiation/ultraviolet light. If  left unrepaired, the damage will lead to cell 
death. Luckily, the cell has developed natural processes to fix breaks. Repair 
can follow one of  two paths: non-homologous end joining (NHEJ) or 
homology-directed repair (HDR).1 
NHEJ is a fast simple method, generally favoured when broken ends are 
compatible.2 Here, specific proteins guide the alignment of  the broken ends, 
WRITTEN BY DANIEL OSBORN
CRAFTING THE
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Recent advances in genome editing are revolutionising the way we tackle big scientific questions.  
Tools have been developed that act like tiny ‘molecular scissors’, causing targeted genomic cuts in 
DNA. By exploiting cells’ innate DNA repair mechanisms, scientists can repair aberrant genes or modify 
the genetic code to their liking. With these tools, we can correct pathogenic mutations, model human 
genetic disease in cells and animal systems, modify key organisms for biotechnology and agriculture, 
and potentially eradicate hereditary monogenic disease.
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experiments in human embryos (not destined for transplantation) used 
CRISPR/Cas9 and synthetic DNA template-mediated HDR to correct 
a mutation in MYBPC3, which normally causes sudden death syndrome.9 
Despite the obvious ethical issues surrounding the misuse of  genome 
editing to manipulate human genetics, there are serious concerns regarding 
inherited off-target effects that must be resolved before reaching the clinic. 
DISSECTING THE ZEBRAFISH GENOME
Although genome editing continues to raise concerns for clinical use, it 
has provided immediate advances in modelling disease in animals. The 
zebrafish is one such organism that has benefited from improved genome 
editing techniques. Popular for its versatility as an in vivo model, the 
zebrafish provides rapid ex utero development, large numbers of  embryos, 
ease of  genetic and pharmaceutical manipulation, and over 82% disease-
causing genes in common with humans.17 For many years, antisense 
morpholino (MO) technology has been used to knockdown gene function 
in zebrafish, by inhibiting gene-specific translation. However, MO use has 
come under scrutiny in recent years.18 Mutant zebrafish lines remain the 
‘gold standard’, although generating them in the past required laborious 
large scale teratogen-based screens.19,20 Although many mutants have been 
recovered for a large number of  genes, many more have been missed. 
The targeted nature of  CRISPR/Cas9 has meant that zebrafish mutations 
in genes known, or suspected, to be pathogenic can be easily disrupted 
as a consequence of  error prone NHEJ.21 Although it is possible to create 
exact mutations that recapitulate patient variants by the addition of  
synthetic DNA templates for HDR, this is more challenging.22 However, the 
technology is constantly evolving; variations in endonuclease activity are 
being developed to improve specificity and efficiency.23 
These are exciting times. Genome editing has become commonplace in 
most research laboratories and the possibilities for manipulating genomic 
DNA for scientific advances are endless.
DANIEL OSBORN
Senior Lecturer in Genetics, Genetics Research Centre at St 
George’s, University of London
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forming homology-searching nucleoprotein filaments.6 The filaments hunt 
for sequence homologies in sister chromatids, which guide repair.7 Again, 
adept scientists have manipulated this process to knock-in genetic material 
to loci, repairing genetic variants or adding traceable tag proteins.8,9 Thus, 
DNA repair by NHEJ or HDR forms the basis of  the genome editing 
technique.
MAKING PRECISE CUTS
Genomic breaks caused by natural forces are unpredictable and occur 
randomly. To use DNA repair mechanisms for scientific gains, researchers 
have developed precision DNA cutting tools. Although other genome 
editing tools exist (meganucleases, zinc finger nucleases and transcription 
activator-like effector nucleases or TALENS10), CRISPR/Cas9 (clustered 
regularly interspaced short palindromic repeats with CRISPR associated 
protein 9) has proved to be efficient and accessible to researchers. 
Coined as ‘the discovery of  the century’, the two scientists attributed to 
its identification, Jennifer Doudna (Berkeley, CA, USA) and Emmanuelle 
Charpentier (Berlin, Germany),11 have been tipped to win a Nobel Prize for 
their work, along with Feng Zhang (Cambridge, MA, USA), a pioneer in 
the use of  CRISPR/Cas9 on mammalian cells.12 
First discovered as a bacterial adaptive immune response to foreign invading 
viral DNA,13 the system acts to incorporate specific portions of  phage DNA 
into the CRISPR loci. This allows generation of  homology-searching guide 
RNAs that bind with Cas9 endonuclease and target cuts in the viral DNA.13 
Synthetic guide RNAs can be designed to incorporate user-defined target 
sequences, and synthesised in the laboratory. Therefore, the CRISPR/Cas9 
system offers a versatile and adaptive tool for generating targeted genomic 
breaks.
A TOOLKIT TO TREAT DISEASE
CRISPR/Cas9 is a powerful tool and has been used to remove an erroneous 
exon from the dystrophin gene in mice with muscular dystrophy, resulting in 
restored muscle integrity and function.14–16 Furthermore, proof  of  principle 
A simplified schematic of CRISPR/Cas9-directed genome editing. 
(a) CRISPR/Cas9 complex is used to target genomic DNA breaks, like 
‘tiny molecular scissors’. (b) DNA breaks can be repaired by either non-
homologous end joining (NHEJ, left) or homology-directed repair (HDR, 
right). (c) NHEJ is error prone, resulting in mutations in targeted genes, 
permitting gene function experiments. HDR can be used to replace genetic 
information, mimicking or correcting pathogenic sequences (e.g. for 
disease modelling or personalised medicine respectively). ©D Osborn
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(c) Repair complete
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One reason for this ‘special’ status is the potential to ‘unlock’ information 
that has health implications for a wider circle of  family members, for which 
the patient becomes gatekeeper. As a consequence, the genetic counselling 
and consent process has typically involved pre-emptive discussions on 
the implications of  the test results, the willingness of  the patient to share 
relevant genetic data with family members and, if  appropriate, issues 
relating to the risks to existing and future offspring.
However, as the landscape of  genetic testing changes, so do the 
considerations relevant to counselling and consent. For example, whilst 
traditional single gene tests for highly penetrant monogenic disorders have 
typically given binary results (i.e. positive or negative), the shift towards 
high-content testing (e.g. disease-targeted gene panels, whole genome 
sequencing (WGS)) raises many additional issues, not least a substantially 
increased likelihood of  identifying uncertain test results (e.g. variants of  
uncertain significance, see below) or clinically relevant findings incidental  
to the indication for testing (i.e. ‘incidental findings’). 
Indeed, the potential complexities of  current high-content testing strategies 
ensure that it is not feasible to discuss all hypothetical outcomes of  testing, 
although the possibility of  ambiguous test results and/or IFs should be 
discussed, and specific consent sought to determine if  ‘actionable’ IFs are to 
be disclosed.
Furthermore, high-content testing raises additional ethical considerations, 
including those relating to long term data storage, data sharing (whilst 
preserving patient privacy) and how to deal with newly available 
information that may impact upon earlier test results (e.g. variant  
re-classification, or emergence of  new testing strategies). 
It seems likely that, in the longer term, out of  necessity, we will become 
more pragmatic about genetic data, and its ‘special’ status will diminish. 
In addition, the continued exponential rise in genetic testing ensures that 
existing models of  care, based on one-to-one genetic counselling, are 
increasingly impractical. 
Looking forward, it remains unclear how the consent process will evolve, 
although this is likely to be shaped by a combination of  ethical concerns 
and practical considerations. 
VARIANT INTERPRETATION:  
DEALING WITH UNCERTAINTY
The clinical utility of  a given genetic test is dependent on the accuracy  
with which the result predicts a health outcome in the individual. For 
monogenic disorders this is dependent on several factors, including the 
disease penetrance (i.e. the likelihood that a mutation carrier will manifest 
disease), clinical expressivity (i.e. the range of  phenotypes associated with 
the genetic abnormality) and, perhaps most importantly, the accuracy 
of  variant interpretation. Unfortunately, many of  our prior assumptions 
regarding these factors have turned out to be inaccurate. For example, both 
reporting and ascertainment biases have led often to estimates of  
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As the opportunities to undertake genomic 
sequencing in the clinical setting expand, 
physicians play an increasing role in the genetic 
testing process, both at the point of request 
and in receiving and communicating results. It 
is therefore paramount that doctors keep pace 
with all aspects of the genetic testing workflow, 
to provide high quality care. Here, Paul Newey 
considers the latest issues you can expect to 
encounter in the clinic.
Barely a week passes without a story hitting the headlines, heralding a 
major medical breakthrough only made feasible by the recent advances in 
DNA sequencing technology: ‘Shark DNA could help cure cancer’ ‘Skinny 
genes the secret to staying thin’ ‘Can your DNA tell you what to eat?’1
Inevitably, such stories raise public expectations regarding the potential 
utility of  genetic testing to improve health, and the impact on the public 
consciousness is borne out by an increasing demand for direct-to-consumer 
testing, offered by a growing number of  commercial providers. 
In the UK, successive governments have displayed similar enthusiasm for 
genetic testing, supporting major initiatives such as Genomics England’s 
100,000 Genomes Project and, more recently, announcing an ambition to 
map 5 million genomes over the next 5 years.2 
Although such large scale sequence projects can feel far removed from day-
to-day medical practice, the indications and opportunities for genetic testing 
in the clinical setting continue to accelerate, such that all doctors require 
a working knowledge of  the genetic testing process that is fit for purpose. 
This includes having the clinical acumen to select and utilise genetic 
tests appropriately, as well as the necessary tools to communicate results 
accurately and effectively to patients and their families.
Indeed, as genetic testing moves from dedicated clinical genetics services 
into mainstream medical clinics, physicians need to be aware of  the many 
challenges associated with contemporary testing. Two such areas include 
‘What constitutes informed consent?’ and ‘What should we do when we 
receive uncertain test results?’
INFORMED CONSENT:  
IS GENETIC TESTING SPECIAL?
In the minds of  both the medical profession and the general public, 
genomic data carry a special status. As a consequence, genetic testing has 
typically involved the provision of  genetic counselling prior to seeking 
informed consent. 
‘… as genetic testing moves from 
dedicated clinical genetics services into 
mainstream medical clinics, physicians 
need to be aware of the many challenges 
associated with contemporary  
testing.’
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‘Looking forward, it remains unclear 
how the consent process will evolve, 
although this is likely to be shaped by 
a combination of ethical concerns and 
practical considerations.’
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However, several studies have reported an unexpectedly high frequency 
of  apparent mutation carriers in the background population, indicating 
that the implementation of  such population-level testing would probably 
result in a huge demand for downstream tumour surveillance programmes.3 
Therefore, until we have more robust methods for variant interpretation 
and establishing accurate estimates of  disease penetrance, such population-
level approaches are likely to prove problematic. 
Outside the confines of  the medical clinic, the recent US Food and Drug 
Administration (FDA) approval of  the first direct-to-consumer genetic 
testing for a limited number of  BRCA1/BRCA2 mutations suggests a public 
appetite for primary prevention genetic testing,8 and, increasingly, patients 
are likely to attend medical clinics with the results of  genetics tests from 
private providers. Doctors will need the skills to understand these test results 
and to determine appropriate courses of  action. 
Finally, despite the enormous apparent progress, it remains unclear to  
what extent the genetic testing revolution will deliver truly transformative 
health benefits. As we approach the 20-year anniversary of  the completion 
of  the first draft of  the Human Genome Project, it is worth reflecting 
how far (or not) we have come. Announcing this event in June 2000, US 
President Bill Clinton stated: ‘Genome science will have a real impact on  
all our lives – and even more, on the lives of  our children. It will 
revolutionise the diagnosis, prevention and treatment of  most, if  not all, 
human diseases.’9 Nearly two decades later, we remain a long way from 
such aspirations and, until our understanding of  the complexity of  genetic 
information and its relevance to health improves, the utility of  genetic 
testing on a global level may be modest. In reality, the field of  clinical 
genetic testing remains at the start of  its journey. As a profession,  
we probably have no choice but to climb on board, albeit ensuring we  
have a life jacket packed.
PAUL J NEWEY
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School, University of Dundee
disease penetrance being substantially overstated, whilst recent large scale 
sequencing projects have resulted in many previously reported pathogenic 
variants being reclassified as benign.3,4 
The majority of  molecular genetic laboratories now adopt the American 
College of  Medical Genetics and Genomics (ACMG) guidelines for 
variant interpretation, which consider multiple variant- and gene-specific 
features, to categorise variants into one of  five groups (‘pathogenic’, ‘likely 
pathogenic’, ‘variant of  uncertain significance’ (VUS), ‘likely benign’, 
and ‘benign’).5 However, variant interpretation remains imprecise and 
these groups are not absolute. The VUS designation occurs when there 
is insufficient evidence to support a more definitive interpretation (either 
benign or pathogenic), often arising when relevant information is either 
absent, incomplete or conflicting. With high-content tests, this situation 
arises frequently, reflected by the observation that ~40% of  all variants in 
the ClinVar database have a VUS designation.6 
Unfortunately, the ‘uncertainty’ of  a VUS result can spread to the  
clinician’s decision-making. Whilst, by definition, the VUS category is not 
sufficient to make a molecular diagnosis, it is important to consider the 
result in the overall clinical context of  the patient. For example, how does 
the result ‘fit’ with the clinical phenotype and family history? This may 
help to establish if  further clinical follow up or investigation is warranted. 
In addition, acknowledging that the VUS category covers a range of  
probabilities, maintaining good lines of  communication with the clinical 
and molecular genetics team may allow a more refined estimate of  disease 
risk. When a VUS is identified, cascade testing of  asymptomatic family 
members is not usually appropriate, although the testing of  affected 
members may increase (or refute) support for pathogenicity. 
Finally, it is important to highlight that variant interpretation should not be 
considered as a static one-off event, but rather as a dynamic process that may 
change as new information comes to light. As such, establishing procedures 
that allow periodic re-evaluation of  variants is likely to be of  benefit.
STEAMING FORWARD OR ‘ICEBERG AHEAD’?
The recent rapid progress in DNA sequencing technology has far outpaced 
our ability to accurately interpret the huge wealth of  data generated. 
However, as the costs of  high-content genetic tests plummet to those of  
other routinely used diagnostic tools (e.g. cross-sectional imaging), it seems 
unlikely that, as a profession, we will be able to resist the temptation to 
deploy testing on a population scale.
For example, many already advocate population-level primary screening 
for the first wave of  hereditary cancer predisposition genes (e.g. BRCA1, 
BRCA2, MLH1, MSH2),7 whilst arguments extending such testing to 
additional genes, including those associated with monogenic endocrine 
tumour disorders (i.e. SDHB, SDHD, MEN1, VHL, RET ) are not likely to be 
far behind. 
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‘The recent rapid progress in DNA 
sequencing technology has far outpaced 
our ability to accurately interpret the 
huge wealth of data generated. However, 
it seems unlikely that we will be able to 
resist the temptation to deploy testing on  
a population scale.’
‘… until our understanding of the 
complexity of genetic information and 
its relevance to health improves, the 
utility of genetic testing on a global level 
may be modest.’
On the face of it, the rising tide of obesity seems to have little to do with genetics. As a society, we  
eat more and move less than we need to. Weight gain and, in time, obesity (body mass index (BMI) 
>30kg/m2) follow. However, in an environment where highly palatable, calorie-dense food is cheap  
and easily available, many people maintain a normal body weight, and some are particularly thin.  
Why are people so dierent? 
A commonly held view is that people who are obese choose to eat more 
and to exercise less. Obesity is seen as a direct consequence of  a lack of  
willpower and self  control: ‘It’s their fault!’ While some people do eat 
more and move less than others, genetic factors strongly influence these 
behaviours, and when faced with more calories than we need, genetic 
factors also influence the amount of  weight we gain. 
HOW STRONG IS THE EVIDENCE?
Studies of  families, of  identical and non-identical twins and of  children who 
were adopted, all indicate that 40−70% of  the variation in weight between 
people is heritable. In a landmark (indeed, heroic) Canadian study, 12 pairs 
of  identical male twins lived under constant supervision for 100 days. They 
were given a diet that exceeded their energy requirements by 1000 calories 
a day. Not surprisingly, they all gained weight.1 The amount gained varied 
considerably across the group but was very similar between members of  
a twin pair. Similarly, twins given a reduced calorie diet lost very similar 
amounts of  weight, but across the group there was a lot of  variation.
Inherited factors influence how much food we eat, levels of  fullness/satiety 
in response to a fixed meal, basal metabolic rate and the physiological 
response to a fixed amount of  exercise. Lee Kaplan and colleagues showed 
that the response to bariatric surgery (Roux-en-Y bypass) is highly heritable.2 
PUTTING A NUMBER ON IT
One way of  assessing the contribution of  many different genetic variants 
to a person’s BMI is to add up their effects to derive a risk score. BMI risk 
scores derived from hundreds of  common variants found in genome-wide 
association studies are higher in obese people than in normal weight people, 
and very low in extremely thin people.3 
Recently, Katherisan and colleagues tapped into genetic data from  
0.5 million people involved in UK Biobank. By adding up the contribution 
of  2 million variants they derived a risk score that, for the first time, predicts 
obesity from age 12 years onwards.4 Their work, alongside that of  others, 
now unequivocally shows that the dice are loaded against people who 
develop obesity, and in favour of  others who carry variants that protect 
them from developing obesity5 and allow a subset of  people to stay very 
thin.3 
DOES THIS HELP PATIENTS?
Some healthcare professionals (and indeed politicians) worry that knowing 
obesity is so strongly influenced by genes will give people permission to eat 
 THE ENDOCRINOLOGIST | SUMMER 2019 | 17
what they like ‘because it’s all genetic’. In practice, this seldom happens. 
Thinking about other clinical areas, if  we recognise the real difficulties that 
people have with their weight, and why, then we may be able to have a 
more constructive relationship with patients with severe obesity, which can 
only be a good thing when managing chronic conditions. 
Genetic testing (now available in the NHS) is particularly important  
in people who develop severe obesity at a young age (before the age of   
5 years), who have a high chance of  carrying penetrant variants which 
disrupt the hormone leptin and the hypothalamic neuropeptides and 
receptors involved in leptin signalling. One condition, albeit rare, responds 
dramatically to therapy, and there are other genetic obesity syndromes for 
which targeted clinical trials are ongoing (www.goos.org.uk). Importantly, 
a genetic diagnosis challenges those who advocate removing children with 
severe obesity from the care of  their own families. 
CAN GENETICS REVEAL NEW DRUG TARGETS?
There are likely to be hundreds, perhaps thousands, of  genes that affect a 
person’s weight. Finding these genes remains a powerful tool for discovering 
the mechanisms that regulate weight, which can, in turn, highlight new 
approaches to therapy.
One example of  a potential target informed by genetic studies is MC4R 
(melanocortin 4 receptor), a G protein-coupled receptor which acts in the 
brain to suppress appetite. People who have variants that disrupt MC4R 
gain weight easily. Different variants in MC4R that increase its activity by 
signalling through the β-arrestin pathway are associated with protection 
from obesity and its metabolic complications.5 These studies suggest that 
drugs that mimic the protective variants could provide new, safer, weight-
loss therapies.
So, finally, the evidence is piling up. When it comes to developing obesity, 
it is now very clear: the odds are stacked against some people and in favour 
of  others. 
SADAF FAROOQI
Wellcome Principal Research Fellow, Professor of Metabolism and 
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‘There are likely to be hundreds, perhaps 
thousands, of genes that affect a person’s 
weight.’
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3. Diagnosis in ethnic groups
Whilst initial studies to identify monogenic diabetes have focused on white 
European populations, there is now increasing recognition of  monogenic 
diabetes in people of  other ethnicities.16 However, a 2016 study revealed 
that the detection rate for MODY in South Asian people referred for 
genetic testing was much lower than in people of  white ethnicity.17 It is 
likely that more people will need to be tested from ethnic groups with a high 
prevalence of  young-onset type 2 diabetes, as the separation of  MODY from 
type 2 diabetes is challenging on the basis of  clinical features and existing 
biomarkers.18
4. Understanding test results
Anyone undertaking genetic testing in their practice will have come across 
novel mutations or variants of  unknown significance (VUS) in genetic testing 
reports.19 Understanding what these results mean, whether they should be 
conveyed to the patient and how they might impact treatment is challenging. 
Co-segregation studies in family members can be a powerful tool, along 
with detailed clinical phenotyping, to disentangle pathogenicity.20 Sometimes 
clarity around diagnosis cannot be provided, and it is good clinical practice 
to keep a record of  patients with these variants which can be revisited 
regularly with the molecular genetics service, as more knowledge becomes 
available.
NEW DEVELOPMENTS IN THE FIELD
To date, the field of  diabetes genetics has focused on detecting monogenic 
disorders, but now attention is turning to utilisation of  information about 
the polygenic risk of  diabetes. Single nucleotide polymorphisms (SNP) can 
modify the risk of  type 1 and type 2 diabetes, both polygenic conditions. 
Summing up the risk of  individual SNP genotypes can provide a composite 
polygenic risk score. In diabetes, these risk scores have been used to support 
diabetes classification, given the challenge of  differentiating type 2 diabetes 
from adult-onset type 1 diabetes and also MODY.21,22 The impact of  using 
this clinical information and its applicability in all ethnicities have yet to be 
determined, and those in the field await further studies.23
SHIVANI MISRA
Consultant in Diabetes and Metabolic Medicine, Imperial College 
Healthcare NHS Trust, London
The recognition of  a monogenic form of  diabetes dates back to the 1970s, 
when Robert Tattersall first described maturity-onset diabetes of  the young 
(MODY).1 As knowledge of  the condition has expanded, the initial criteria 
outlined (autosomal dominant inheritance, age of  diagnosis <25 years and 
no insulin requirement) have been found to recognise some, but not all cases 
of  MODY.2
Today, the term monogenic diabetes incorporates not just MODY but  
other single gene defects causing diabetes, including neonatal diabetes 
(diabetes presenting at age <6 months) and mitochondrial diabetes 
(maternally inherited mutations in mitochondrial DNA). 
The prevalence of  monogenic diabetes varies according to the population 
studied and how they were selected for testing. MODY accounts for between 
roughly 1 and 4% of  diabetes in those diagnosed below 30 years,2,3 whilst 
neonatal diabetes is less common and affects approximately 1 in 100,000 
births.4
BENEFITS OF DIAGNOSIS
The impetus to identify monogenic diabetes comes from variable  
treatment options that depend on the affected gene. In many cases, these 
options are superior to the standard care provided to people with type 1 or 
type 2 diabetes, so there is individual clinical benefit in identifying cases. 
Mutations in hepatocyte nuclear factor-1α (HNF1A) and -4α (HNF4A),  
β-cell transcription factors, are best managed with low doses of  
sulphonylureas.5,6 Glucokinase (GCK) MODY, involving a key enzyme in 
glycolysis, requires no treatment at all7,8 and mutations in hepatocyte nuclear 
factor-1β (HNF1B) are usually insulin-requiring.9 In neonatal diabetes, the 
most commonly affected genes are KCNJ11 and ABCC8, encoding the two 
subunits of  the ATP-sensitive potassium channel of  the β-cell.4 High dose 
sulphonylurea therapy can be used in >90% of  cases, without the need for 
insulin therapy and associated complications in affected neonates.10 
In addition to being more precise about treatment,5,11,12 making a  
diagnosis of  monogenic diabetes has other benefits, including cascade 
testing in family members to identify other cases, and early identification of  
other features that may be associated with the genetic defect, for example 
renal abnormalities in people with HNF1B MODY.9 Additionally, delays 
in diagnosis can impact treatment success. People with HNF1A mutations 
achieved better glycaemic control the earlier a genetic diagnosis was made,13 
and in children with permanent neonatal diabetes, failure to transfer to 
sulphonylurea treatment completely was associated with a longer duration  
at the time of  transfer from insulin.10
WHAT ARE THE CURRENT CHALLENGES?
1. Considering the possibility of  diagnosis
A significant proportion of  MODY cases remain misdiagnosed as type 1  
or type 2 diabetes, whilst new cases are not always recognised, even at 
diagnosis.14 The marked geographical variation in frequency of  genetic test 
requests signals variation in clinical practice, but this heterogeneity is likely 
to improve following efforts from the Exeter Molecular Genetics team to 
improve education, and a network of  genetic diabetes nurses to facilitate 
training and testing.15 
2. Deciding to test
A stratification process is required to identify the cases most likely to have 
monogenic diabetes. For neonatal diabetes, this is relatively straightforward, 
as the phenotype of  developing diabetes in the first 6 months of  life is 
unambiguous, nearly always monogenic, and testing is available free of  
charge.4 For cases of  MODY, clinical stratification (selecting those diagnosed 
below 30 years) with biomarkers (selecting only those negative to pancreatic 
autoantibodies, with some evidence of  endogenous C-peptide production) 
seems to be the most effective approach.2
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cancer is almost always present, and this type of  testing is therefore called 
a ‘rule-in’ test.5 
However, RAS mutations may be present in benign thyroid lesions 
and driver mutations are unknown for about 5% of  differentiated  
cancers, so false-positive and false-negative results may occur. Nonetheless, 
this approach offers further advantages because the determination of  
BRAF- and RAS-positive status also has prognostic value in addition to 
diagnosing thyroid malignancy. BRAF-positive tumours are more aggressive 
whereas RAS-positive cancers tend to have a more indolent behaviour.6
Gene expression analysis or gene expression classifiers use algorithm-type 
approaches to analyse the expression of  specific genes in panels of  142 
genes.7 Nodules are classed as benign or suspicious, with those identified 
as benign not requiring surgery. This is therefore a ‘rule-out’ test, and a 
pooled analysis of  12 studies concluded that the negative predictive value 
of  the gene expression classifier is 92%, with a malignancy prevalence rate 
of  31%, in the nodules that were studied.8
A further approach to diagnose the presence of  malignancy is the 
determination of  expression of  microRNAs, which are small non-coding 
RNA fragments that regulate gene expression by influencing the stability 
and translation of  messenger RNA. MicroRNAs are relatively stable 
compared with messenger RNA and are differentially expressed in benign 
and cancerous thyroid tissues. Two commercially available kits based 
on microRNA expression in thyroid fine needle aspiration biopsies are 
currently in use.9
MOLECULAR TESTING IN THE NHS
Molecular testing to avoid unnecessary surgery in patients with 
indeterminate thyroid nodules is expensive, ranging from $3000 to $5000 
depending on the test used. The most studied tool evaluated on health 
economic grounds is the gene expression classifier, indicating this to be 
a cost-effective test.10 However, most of  these cost-effectiveness analyses 
are based on modelling rather than actual patient data, and results are 
dependent on the malignancy rates in the population, costs of  surgery and 
surgical complications, healthcare costs and a number of  other factors.
Whilst these molecular analyses are likely to result in reductions in 
unnecessary surgery and patient benefit, the high cost of  testing makes the 
routine use of  these approaches prohibitive in our current NHS system.
KRISTIEN BOELAERT
Reader in Endocrinology, Institute of Metabolism and Systems 
Research, University of Birmingham
FEATUREGENETICS
The majority of  thyroid cancers are differentiated, originating from 
follicular thyroid cells. They usually present as a lump in the neck or  
may be found incidentally during investigation of  unrelated neck disorders, 
including carotid Doppler and cross-sectional imaging approaches. 
Thyroid nodules (lumps) are very common and occur in at least 50% 
of  the population. However, only a small subgroup (5–7%) harbour a 
clinically significant cancer. The initial evaluation of  thyroid nodules 
includes thyroid function testing, to ensure this is normal, and an 
ultrasound assessment. There are a number of  scoring systems which 
combine suspicious ultrasonographic features such as solid composition, 
hypoechogenicity, irregular margins, increased intra-nodular blood  
flow and the presence of  micro-calcifications to predict the risk of  
malignancy. 
Nodules that cannot be deemed benign through ultrasonography need  
to be further investigated through fine needle aspiration cytology (FNAC), 
to help determine the possible presence of  thyroid malignancy.1 
INDETERMINATE THYROID NODULES
Around 20–30% of  cytological evaluations result in indeterminate  
results and usually encompass RCPath Thy3a (neoplasm possible with 
cellular atypia) and Thy3f  (follicular neoplasm suspected), which have  
an overall risk of  malignancy of  10–30% and 25–40% respectively.
Generally, patients with indeterminate nodules undergo surgery to  
remove the half  of  the thyroid gland that contains the thyroid nodule  
for full pathological evaluation, to exclude thyroid malignancy. The use  
of  molecular testing of  FNAC specimens to refine the diagnosis of   
thyroid malignancy has become widely accepted in the USA and in  
some European centres.2
GENETIC ALTERATIONS
The molecular alterations underlying thyroid cancer have been  
unravelled for about 95% of  differentiated tumours. Papillary thyroid 
cancers, which account for about 85% of  all thyroid cancers, usually  
occur following mutations in genes coding for proteins in the mitogen-
activated protein kinase (MAPK) pathway, which regulates the  
proliferation and differentiation of  thyroid cells. A single mutation in  
the BRAF gene (V600E) is found in up to 60% of  papillary cancers, as 
well as in more rare poorly differentiated and anaplastic cancers, which 
originate from papillary cancers following a de-differentiation process. 
Mutations in RAS genes are found in 15% of  papillary cancers and  
in 40% of  follicular cancers, which also belong to the group of  
differentiated cancers, accounting for 2–5% of  all thyroid cancers.3
Hybrid genes, formed following fusion of  two previously unrelated  
genes, such as the RET/PTC oncogene and the PAX8/PPARG gene, are 
found in radiation-induced papillary cancers and in some follicular thyroid 
tumours. More recently, mutations in the telomerase reverse transcriptase 
(TERT) gene and in the TP53 tumour suppressor gene have been described 
in some differentiated tumours, but also, in particular, in undifferentiated 
and anaplastic thyroid tumours.3
MOLECULAR TESTING STRATEGIES
The two most commonly used approaches to evaluate the molecular 
background of  thyroid cancers are mutational analysis and gene expression 
analysis.
In mutational analysis, the DNA from the material obtained through fine 
needle aspiration biopsy of  the thyroid nodule is sequenced to look for 
mutations in BRAF, RAS, TERT, TP53 and other relevant genes, as well as 
to detect fusion genes.4 If  a mutation in these genes is found, then thyroid 
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MOLECULAR MARKERS
IN DIAGNOSING THYROID CANCER  
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OPINION
inherit the changes, potentially leading to unpredictable effects on future 
generations. In reaction to the news, some of  the scientific community 
released a statement asking for a global moratorium on all clinical uses of  
human germline editing.1
Yet, the technology is immensely valuable in disease research and for the 
treatment of  many serious inherited conditions, a distinction highlighted 
in the statement. Unlike the controversial germline gene editing, CRISPR-
based human clinical trials have thus far been limited to somatic cells. In 
other words, as with any experimental drug or treatment, they have no 
consequence for future generations.
For example, earlier this year, CRISPR Therapeutics and Vertex 
Pharmaceuticals announced the first dosing of  a patient with a severe 
haemoglobinopathy using a gene-edited cell therapy, called CTX001, in a 
phase I/II trial.2 This trial involves gene editing the cells outside the body, 
then reintroducing them into the patient. 
The first in vivo (i.e. editing inside the body) CRISPR-based therapeutic, 
EDIT-101, is also being investigated. Editas Medicine Inc. published their 
preclinical data on EDIT-101, which will be administered to patients with  
a genetic form of  blindness.3
 
As with any new therapeutic development, there will be elements of  
uncertainty. However, for families living each day with the real burden 
of  genetic disease, this uncertainty will need to be balanced against the 
potential benefits and, ultimately, patient choice. 
Following decades of  development, there lies ahead an exciting path 
towards finally realising those initial hopes of  gene therapy as a promising 
treatment option for families affected by a rare disease.
YALDA JAMSHIDI
Reader in Genomic Medicine and Head of Genetics Research Centre, 
Molecular and Clinical Sciences Institute, St George’s University of 
London
Diseases such as cystic fibrosis are known as ‘rare’ diseases, but whilst 
individually a rare disease can affect just a handful of  people, collectively 
the numbers are much more alarming. For instance, in the UK alone, up to 
3.5 million people will be affected by a rare disease at some point in their 
lives.
Up to 80% of  these rare diseases are genetic in origin and, with recent 
advances in genetic sequencing technologies, the rate of  successful 
diagnoses has increased dramatically. Unfortunately, for the overwhelming 
majority of  these patients, there is still no treatment.
Since that first disease-gene discovery 30 years ago, researchers have been 
testing different approaches to gene therapy. These have included limiting 
or switching off expression of  the gene, replacing it with a healthy copy, or 
increasing the activity of  an alternative gene that can compensate for the 
deficient one. Success relies on being able to carry out targeted alterations 
of  DNA sequences, but also on the ability to get the gene to the right organ 
– the problem of  gene delivery.
For many years gene therapy trials had limited success, resulting in adverse 
reactions, most notably the case of  Jesse Gelsinger, an 18-year-old with a 
rare liver disorder, who died from multiorgan failure following gene therapy 
in 1999. 
Any new treatment or drug comes with a risk of  adverse events. However, 
in the case of  an individual rare disease, standard trial designs often cannot 
be easily optimised to obtain adequate safety and efficacy data, due to the 
small numbers of  patients available. As a result, alternative designs have 
had to be developed. Thanks to legislative incentives for developing orphan 
drugs to target rare diseases, there has been substantial progress over the 
past 20 years.
Excitingly, a string of  recent success stories has returned some hope to 
the field. These have included the first US Food and Drug Administration 
(FDA)-approved gene therapies for an inherited eye condition (RPE65-
mediated retinal dystrophy), and a severe neuromuscular condition (spinal 
muscular atrophy; SMA), and phase 3 gene therapy trials for a severe  
skin-blistering condition (epidermolysis bullosa).
Another important recent development has been the advent of  a new 
powerful technique for gene editing, known as CRISPR. This technique 
allows researchers to edit DNA much more cheaply, accurately and simply 
than ever before. It has quickly led to a series of  clinical trials to test safety 
and efficacy of  CRISPR-mediated gene therapies for debilitating genetic 
diseases.
CRISPR relies on the use of  proteins used by bacterial cells to fight  
viruses. For effective gene delivery it is often coupled with the use of   
adeno-associated viruses (AAVs). These viruses have been modified to 
function as delivery agents. They have been used over the years in gene 
therapy trials, including, for example, the recent successful SMA trial. 
However, since CRISPR technology is relatively easy to implement, it 
can also be abused. Last year, news of  an unregulated, unethical use of  
CRISPR technology to edit the DNA of  otherwise healthy human embryos 
threatened to slow down the excitement and progress of  CRISPR-based 
gene therapies. Altering genes in human embryos means that offspring will 
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GENE THERAPY:
A NEW HORIZON
‘Whilst individually a rare disease can affect 
just a handful of people, collectively the 
numbers are much more alarming … in the 
UK alone, up to 3.5 million people will be 
affected by a rare disease at some point in 
their lives.’
In 1989, the discovery of the gene that is defective in the childhood disease cystic fibrosis brought 
about the hope of treating this, and similarly devastating genetic diseases, by targeting the defective 
gene itself. We call this approach gene therapy.
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Celebrating and rewarding  
EXCELLENCE IN ENDOCRINOLOGY
APPLICATIONS OPEN FOR 
ENDOCRINE NURSE AWARD
Are you a nurse leading an innovative initiative in endocrinology? 
Do you know an endocrine nurse that deserves recognition for their 
contributions to patient care, education or research? 
Apply, or nominate a colleague, for the 2020 Endocrine Nurse Award by 8 July 2019.
For more details visit www.endocrinology.org/grants-and-awards/prizes-
and-awards/endocrine-nurse-award. 
DALE  
MEDALLIST
Constantine Stratakis
Bethesda, MD, USA
SOCIETY  
MEDALLIST
Philippa Saunders
Edinburgh, UK
STARLING  
MEDALLIST
Markus Ralser
London, UK
TRANSATLANTIC 
MEDALLIST
Michael Whyte
St Louis, MO, USA
EUROPEAN  
MEDALLIST
Felix Beuschlein
Zurich, Switzerland
INTERNATIONAL 
MEDALLIST
Roger Cone
Ann Arbor, MI, USA
JUBILEE  
MEDALLIST
Julian Davis
Manchester, UK
HELP CHOOSE OUR  
2020 MEDAL WINNERS
Who do you think deserves to be recognised for their 
contributions to endocrinology next year?
For more details and to nominate, visit www.
endocrinology.org/grants-and-awards/prizes-and-
awards/medals.
Nominations must be received by 8 July 2019.
Join us in congratulating our 2019 Society medal winners, world leaders in endocrinology, whose work 
continues to advance our knowledge and clinical practice in endocrinology. Our medallists will present 
plenary lectures at the Society for Endocrinology BES conference 2019 on 11–13 November in Brighton.
MEDAL LECTURERS
SOCIETY NEWS
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Inspiring future endocrinologists  
WITH A TASTE OF SfE BES
Well that’s exactly what the Society has been able to offer around 50 lucky 
school pupils each year, starting at the Society for Endocrinology BES 
conference 2017 in Harrogate. The aim is to bring endocrinology to life 
and to demonstrate its value in the everyday world and in careers. 
The Society for Endocrinology BES conference 2018 in Glasgow was 
no different, and we welcomed pupils from local Glaswegian schools to 
the Scottish Event Campus to come and meet the scientists, nurses and 
clinicians who make up the Society’s membership.
For one afternoon during the conference, pupils were able to attend 
their own dedicated conference session, which started with an overview 
of  hormones given by Maralyn Druce. Pupils then rotated around four 
hands-on activities that provided them with a taste of  some of  the many 
flavours of  hormone science, from ‘pin the hormone’ (Rosemary Bland & 
Matt Simmonds) and ‘cell signalling’ (Nigel Page) to ‘circadian rhythms’ 
(Francesca Spiga) and ‘blood glucose’ (Channa Jayasena & Lisa Shepherd).
The cell 
signalling even 
included its own 
light and sound 
display, while 
Matt Grant had 
devised a series 
of  Society for 
Endocrinology-
branded QR-
coded cards, 
which students 
could take home in order to learn more about hormones at their leisure, by 
linking to the Society’s You and Your Hormones website  
(www.yourhormones.info).
Two networking sessions followed, one each for scientific and clinical 
careers, with plenty of  time for pupils to ask all their questions in an 
informal setting. 
What would it have been like for you to experience your first 
Society for Endocrinology BES conference even before you 
finished school, when you were still embarking on your first  
steps towards a scientific or medical career? 
“
The schools’ conference session provided a great way for members to  
get involved in showcasing some of  the Society’s public engagement 
activities. We are grateful to the 22 members who volunteered at this  
year’s event.
And what did the pupils and their teachers have to say?
It gave me a first-hand perspective on how individual various careers are.
I learned from real-life scientists about the things/experiences I need for my future.
It made me certain that my choice of  career was for me.
The practical aspect was engaging and enjoyable.
Pupils, Schools’ Conference Session, 2018
Thank you for a lovely afternoon, it was very informative.
All the scientists and medics were lovely and very approachable,  
and the pupils have gained a lot from this.
Teachers, Schools’ Conference Session, 2018
“ 
YOU TOO CAN BE INVOLVED!
We are already planning for the Society for Endocrinology BES conference 
2019 in Brighton in November. Perhaps you are considering your first steps 
into public engagement 
and want to learn a bit 
more? Maybe you have 
a fantastic activity you’d 
like to showcase?
Alternatively, if  you’ve 
got an idea that you 
would like to develop 
and demonstrate, you 
could apply for one 
of  the Society’s Public 
Engagement Grants 
(see page 3, deadline 
25 September 2019). 
Whichever way, please  
do get in touch. 
It is very rewarding  
and enjoyable to  
get involved in public engagement and outreach with the Society! For 
further informal discussion about getting involved, please contact  
media@endocrinology.org.
NIGEL PAGE
Public Engagement Committee member and Endocrine Ambassador 
at Kingston University London
SOCIETY NEWS
Join us on the 11–13 NOVEMBER 2019  
for this year’s SfE BES conference!
Come to Brighton and connect with hundreds of  
friends, colleagues and newcomers to the UK’s  
biggest endocrine community. Exchange knowledge  
and experiences, create new opportunities to  
collaborate and strengthen your outcomes in  
endocrinology at SfE BES 2019.
A NEW, MODERN PROGRAMME minimises the chances of frustrating clashes by reducing the  
parallel streams from four to three whilst ensuring both oral communications and symposia are run in tandem.
We’re also extending lunch to 90 minutes, giving you the time you need to network with friends and colleagues, visit the exhibition 
hall and comfortably attend industry symposia.
These improvements combine to provide you with the best SfE BES experience to date.
EMPOWERING THE 
ENDOCRINE NETWORKS
The Society’s Endocrine Networks have 
created a community of Society members 
working in a particular subspecialty of the 
field. Connect with peers and international 
leaders in your area of expertise for a focused 
symposium on Wednesday 13. Attendees 
will meet colleagues experiencing the same 
challenges and looking for opportunities to 
collaborate.
The Endocrine Network sessions are:
• Adrenal and Cardiovascular
• Bone and Calcium
• Endocrine Consequences of Living with 
and Beyond Cancer
• Endocrine Neoplasia Syndromes
• Metabolic and Obesity
• Neuroendocrinology
• Reproductive Endocrinology and Biology
• Thyroid
THE SfE THEATRE is the brand new presentation area at the  
heart of this year’s exhibition hall. This new space provides you with 
numerous opportunities for learning, with ‘lightning talks’ and bespoke 
product demonstrations relevant to your specialism.
INNOVATION SESSIONS will cover clinical, basic science and 
industry innovation crucial to your work. Attend and expose yourself to novel 
technologies, developments in clinical practice and new opportunities for 
funding. You’ll also gain awareness of opportunities for collaboration that 
have yet to be discussed anywhere else.
TUESDAY IS FOR NURSES thanks to a streamlined programme, 
built with nurses in mind. This year’s nurse events avoid clashes with the 
equally popular ‘How do I’ sessions, ensuring you can attend all activities 
aimed at improving your clinical outcomes. It’s also easier than ever to 
meet and network with fellow nurses at our social evening on Monday and 
dedicated lunch session on Tuesday.
Get excited  
ABOUT BRIGHTON
Find out what’s new at 
www.endocrinology.org/sfebes2019
Find out what’s new at 
www.endocrinology.org/sfebes2019
ABSTRACT  
SUBMISSION DEADLINE
1 July 2019 (23.59 BST)
EARLY BIRD  
REGISTRATION  
DEADLINE
5 September 2019  
(23.59 BST)
GET THE LATEST  
INFORMATION
     #SFEBES2019
Save  
the date
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SOCIETY NEWS
Expand your professional community  
CONNECT WITH YOUR  
ENDOCRINE NETWORKS
The Society’s Endocrine Networks are designed to enable  
basic and clinical researchers, clinical endocrinologists and  
endocrine nurses to share knowledge and best practice, and to  
work together to advance their specialist fields. Find out more at 
www.endocrinology.org/membership/endocrine-networks.
ADRENAL AND  
CARDIOVASCULAR
Scott MacKenzie Glasgow
METABOLIC  
AND OBESITY
Barbara McGowan London   
Kevin Murphy London
BONE AND CALCIUM
 Jeremy Turner Norwich 
Caroline Gorvin Birmingham
NEUROENDOCRINOLOGY
Niki Karavitaki Birmingham  
Craig Beall Exeter
NEW! ENDOCRINE  
CONSEQUENCES OF  
LIVING WITH AND  
BEYOND CANCER
Helen Simpson London 
Claire Higham Manchester
REPRODUCTIVE  
ENDOCRINOLOGY  
AND BIOLOGY
Andrew Childs London  
Kim Jonas London
ENDOCRINE NEOPLASIA  
SYNDROMES
Paul Newey Dundee
THYROID
Carla Moran Cambridge
MEET YOUR ENDOCRINE NETWORK CONVENORS
INTRODUCING OUR NEW ENDOCRINE NETWORK
ENDOCRINE CONSEQUENCES OF LIVING WITH 
AND BEYOND CANCER 
Endocrine Network convenors Helen Simpson and Claire Higham look forward to hearing from anyone with an interest in research and clinical care 
associated with endocrine-related effects of  cancer. You can contact them on SfE Connect.
Key topics of the Network:
• Endocrine and metabolic consequences of  cancer and cancer therapies
• Electrolyte disturbances such as hyponatraemia and hypo- and 
hypercalcaemia
• Immunotherapy toxicities
• Endocrine consequences of  proton beam therapy
• Bone health
• Progress towards recommending interventions and surveillance 
strategies
CONSEQUENCES OF LIVING  
WITH & BEYOND CANCER
ENDOCRINE NETWORKS
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SOCIETY NEWS
JOINING  
OUR ENDOCRINE 
NETWORKS  
IS EASY:
Log into the Members’ Area at  
www.endocrinology.org/members
Select ‘Endocrine Networks’ 
Tick the all the Networks you’d  
like to join!
WHAT COULD YOU DO WITH  
AN ENDOCRINE NETWORK 
GRANT?
Grants of  up to £5000 are available to support any Network activities, including:
• organising an event
• funding collaborative research initiatives
• employing staff to administer clinical data collection
• supporting any relevant Network activity you can think of !
To find out how to apply, contact grants@endocrinology.org with your proposal.
HELP SHAPE 
YOUR ENDOCRINE 
NETWORK
Want to get more involved with your Network? 
You can apply to be a convenor. Each Network has a 
clinical and a basic scientist focused convenor, for a term 
of  4 years. Society members can apply themselves or 
nominate others. 
Visit www.endocrinology.org/membership/
endocrine-networks to download a nomination form.
JOIN  
SfE CONNECT  
TODAY!
Keeping informed and up-to-date with your Endocrine Networks is now 
even easier. Using the Society’s new online community tool, SfE Connect, 
you can start new conversations to help grow your Network by sharing 
knowledge and best practice and working together to find solutions to 
challenges within your field.
To join, simply visit http://sfeconnect.onsocialengine.com/,  
select ‘Request invite’ and enter your name and email address.
SfE CONNECT can help you:
• Inform other members about what’s new in your field
• Get advice or expertise from Network members 
• Catalyse new collaborations within the Network and  
beyond
• Promote new posts or meetings of  interest to Network  
members
• Arrange offline meetings with members for more in-depth  
discussions
• Discuss any issues relevant to your work and the wider  
endocrine community
• Share knowledge and best practice
Join SfE CONNECT to access exclusive Society for Endocrinology  
BES conference 2019 news and views, especially for SfE Connect 
members!
©Shutterstock
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The lighter, warmer evenings of summer give us  
all greater inspiration to read more and reflect  
upon our careers, and to consider how we are 
evolving and engaging professionally as endocrine 
nurses.
Sofia Llahana’s article introducing Advanced Practice in Endocrinology Nursing, 
the first textbook aimed at nurses, provides us with a thorough appraisal 
of  this publication (see page 29). It is a testament to what can be achieved 
through collaborative work, and importantly includes contributions 
from patients and patient advocacy groups, which support inclusion and 
transparency in shared decision making in patient care. 
The book will support you to advance your practice, underpinned by the 
Society for Endocrinology Competency Framework for Adult Endocrine 
Nursing (Endocrine Connections 2015 4 W1–W17). It is available in print or as 
an ebook so, whether you’re a techie or a technophobe, you can discover 
what it has to offer to you and your departments.
Talking of  amazing successes, Endocrine Nurse Update in Birmingham  
was full to capacity. I would like to thank all of  you who attended 
and actively contributed, as the success is a testament to your active 
participation. 
Our next event will be the Society for Endocrinology BES conference  
in Brighton in November. Please join us for our exciting nurses’ 
programme, which includes two dedicated nurse sessions with eminent 
speakers (see panel and www.endocrinology.org/sfebes2019). I also 
encourage you to submit an abstract (guidance provided on this page) by 
the deadline of  1 July. This will make you eligible for a travel grant to 
attend (www.endocrinology.org/grants-and-awards).
I hope you all have a lovely summer.
BEST WISHES
ANNE MARLAND
ANNE 
MARLAND
NURSE COMMITTEE CHAIR
NURSES’ NEWS
By submitting your abstract to the Society for 
Endocrinology BES conference 2019, you’ll be 
exposing your work to over 1000 clinicians, nurses 
and researchers in endocrinology from across 
the UK and further afield. Those who submit raise 
their profile within their specialty, whilst also 
gaining increased opportunities to collaborate.
There is a specific abstract category for Nursing Practice, and we urge you 
to consider submitting. 
Accepted abstracts are presented at the event as a poster, eposter or oral 
presentation. They will also be published online in Endocrine Abstracts. The 
abstract should be no longer than 300 words (including numbers, symbols 
and tables). The full format and guidelines for abstracts can be seen in the 
online submission form.
The deadline for receipt of  abstracts is 1 
July 2019 (23.59 BST). Submit at www.
endocrinology.org/events/sfe-
bes-conference/sfe-bes-2019/
abstracts.
SUBMIT AN ABSTRACT
TO SfE BES 2019
NURSE SESSIONS  
AT SfE BES 2019
NICE and T3
• T3 replacement: what does 
the evidence suggest?
• The healthcare professional 
and patient consultation − 
informed decision making
• A beginners’ guide: setting up 
a nurse-led thyroid clinic
Management of hyper- and 
hypocalcaemia
• Aetiology of hyper- and 
hypocalcaemia
• Patient management of 
hypercalcaemia and when should the 
surgeon intervene?
• Patient management of hypocalcaemia and  
the patient perspective
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NURSES’ NEWS
INTRODUCING  
ADVANCED PRACTICE IN 
ENDOCRINOLOGY NURSING 
We identified the need for an 
evidence-based published resource 
to support endocrine nurses 
in advancing their practice, 
underpinned by the competence 
frameworks developed by our British 
colleagues.1,2 Significant but isolated 
clinical and research expertise was 
evident amongst our colleagues in 
the UK and internationally. We 
therefore formed an international 
network, in order to develop a 
comprehensive resource to support 
endocrine nurses around the globe. 
These colleagues work at different 
settings and levels of  practice, from 
novice to expert, and from bedside 
nursing to advanced practice 
nursing, running independent  
nurse-led services. 
Recognising the importance of  
multidisciplinary working, we also 
wanted this book to be a useful 
resource for practitioners in other specialties, such as fertility, osteoporosis, 
oncology, urology, gynaecology, and obesity and metabolic disorders, as well 
as specialty trainees, general practitioners, students and expert patients. 
We anticipated and, indeed, faced many challenges in undertaking this 
project, especially as the role of  the endocrine nurse, and nursing training 
and qualifications, vary significantly from country to country. We were, 
however, overwhelmed by the interest we received from colleagues who 
wanted to contribute to this book, echoing the great need for such a 
resource. In particular, this came from physicians and other healthcare 
professionals who recognise the endocrine nurse as a vital member of  the 
multidisciplinary team.
CONTRIBUTORS AND STRUCTURE 
ESE formed our initial working hub and supported this textbook from  
its inception. We created a strong collaborative international network:  
118 eminent authors from 15 countries contributed to this book. Our 
authors are nurses, physicians, surgeons, psychologists, dieticians, clinical 
scientists and geneticists, emphasising the multidisciplinary focus of  the book.
Each chapter includes a comprehensive review of  the anatomy, 
pathophysiology, diagnosis and treatment of  different endocrine conditions, 
supported by the latest evidence and clinical guidelines. Patient stories, case 
studies and examples of  good clinical practice are included, to illustrate 
the impact of  endocrine conditions on patients and their families. These 
also stimulate the readers’ critical thinking and reflection, and make 
information in this book applicable to their practice. Many patient advocacy 
groups contributed case studies and educational resources, supporting the 
importance of  user involvement and shared decision-making in patient care.
The book comprises 13 sections and has a total of  69 chapters. Our section 
editors played a vital role in inviting authors and editing the chapters in 
each section. Each section covers conditions relating to a specific endocrine 
gland (pituitary, adrenal, thyroid, parathyroid and bone disorders, and male 
and female reproduction) and other relevant endocrine conditions, such 
as late effects of  cancer treatment, neuroendocrine tumours, endocrine 
emergencies, and obesity and metabolic disorders. 
There are two sections specific to paediatrics (11 chapters). Paediatric aspects 
have also been incorporated into many other chapters, where relevant. The 
final section focuses on advanced practice nursing, presenting an overview of  
role development and the definition and components of  advanced practice 
nursing, including research. 
IMPLEMENTATION AND FUTURE DEVELOPMENTS 
Advanced Practice in Endocrinology Nursing is currently the only comprehensive 
evidence-based clinical reference for endocrine nurses. As such, it can be 
used alongside the Competency Framework for Adult Endocrine Nursing,2 to support 
the progression of  nurses’ careers ‘from novice to expert’. In combination, 
they provide a framework for nurses to identify their personal educational 
and developmental needs and a ‘one stop shop’ resource to enhance their 
knowledge and competence.
The last section of  the book is particularly useful, as it provides evidence-
based and practical resources to support career progression and role 
development towards advanced nursing practice. 
Division of  the book into sections provides in-depth knowledge for nurses 
who want to develop expertise in specific areas within endocrinology: for 
example, reproduction or women’s health. This presents opportunities 
for professional development and education, by helping nurses to identify 
and bridge knowledge gaps. Each chapter also includes key reading and 
comprehensive reference lists of  significant and current evidence on the 
subject. This can also provide stimuli to generate research questions and 
collaborative multidisciplinary working to improve patient care. 
The book was formally launched at the European Congress of  
Endocrinology on Sunday 19 May 2019. We held two workshops (on 
acromegaly and adrenal insufficiency), illustrating the book’s role in 
supporting development of  evidence-based knowledge, using the Competency 
Framework. We will continue to develop and deliver further workshops and 
online webinars, and anticipate this book will be a key reading reference on 
curricula for advanced nursing practice and endocrine academic courses. 
CONCLUSION
Advanced Practice in Endocrinology Nursing is a testament to what can be 
achieved when everyone works collaboratively towards the shared objective 
of  advancing our profession and improving patient care. We developed a 
comprehensive evidence-based resource, which we hope and trust will assist 
and advise all our colleagues, to ensure the best possible patient care and to 
raise the profile of  endocrine nursing around the globe.
SOFIA LLAHANA
Senior Lecturer and Programme Director, MSc Advanced Clinical 
Practice, School of Health Sciences, City, University of London; Hon 
Consultant Nurse in Endocrinology, University College Hospital, London
WRITTEN BY SOFIA LLAHANA
We are very pleased to introduce the first book ever published for endocrine 
nurses, which has been produced under the auspices of the European Society 
of Endocrinology (ESE).
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Saffron was a thoughtful and supportive colleague and supervisor, who gave 
willingly of  her vast fount of  knowledge and wisdom. Following ‘retirement’ 
Saffron continued to dedicate her time to others and became a governor for 
Oak Lodge School for the Deaf. In addition, she volunteered with the Shaw 
Trust, a charity helping people to rebuild their lives and re-enter work and 
education. Saffron was a keen tennis player and took an active role in the 
local tennis club. 
The recent additions to the family saw her once more also taking an active 
role in childcare, albeit this time being able to hand them back at the end of  
the day!
Saffron’s warmth and wit will be missed by colleagues, students and friends 
alike. She is survived by her husband John Davies, three sons, daughters-in-
law and four grandchildren.
HELEN MASON
Edulink Consultants, Dubai, UAE
Saron Whitehead, Emeritus Professor of 
Endocrinology, sadly passed away on 18 February 
2019. She had been an active member of the 
Society for Endocrinology for many years.
A long-serving member of  the Editorial Board of  The Endocrinologist, 
Saffron was the magazine’s Editor from 2004 to 2005. She was the Chair 
of  the Public Engagement Committee, and also managed press enquiries 
regarding publications and scientific breakthroughs for the Society. Saffron 
was a dedicated advocate for women’s health and worked across the media 
to increase the public awareness of  endocrine issues.
Professor Whitehead graduated from University College London in 1970 
with a degree in physiology. Having come relatively late to her degree, she 
felt that she had finally found her life’s purpose. In particular, she became 
fascinated by endocrinology, moving to McMaster University in Hamilton, 
Ontario, Canada, to study for her PhD in neuroendocrinology. Her first 
publication from this work appeared in Brain Research in 1974. It was soon 
after this that she began to study the impact of  endocrine-disrupting 
chemicals, an area of  research that remained a life-long interest. Her 
expertise made her a national spokesperson on the subject for the press and 
media. 
Moving back to the UK, she joined St George’s Hospital Medical School, 
London, in 1978, as Lecturer in Endocrinology and Reproduction. She 
remained active in research there until her retirement in 2013, after which 
she was granted emeritus status.
Consistently gaining promotion while raising a family, Saffron was an 
important role model for younger female staff in the medical school, being 
one of  only a small number of  female professors at St George’s for most of  
her career. Saffron was a gifted teacher and her endocrinology lectures and 
the specialist course that she established, entitled ‘Science of  Reproduction’, 
were always the most popular. Although officially retired, she remained 
active as a tutor and teacher at St George’s until very recently.
Saffron was prolific author and, in fact, her latest book, Managing Obesity: a 
Practical Guide for Clinicians, was published with co-author Gul Bano earlier 
this year. Across her academic career, she published 55 notable papers, 
five reviews and three endocrinology textbooks. Her textbooks became 
definitive texts on many university degree courses, and she won Academic 
Textbook of  the Year for Endocrinology: an Integrated Approach, authored with 
Steve Nussey.
Saffron wrote widely across her career for publications as diverse as 
New Scientist and The Guardian and she won a sabbatical award from The 
Wellcome Trust to focus on her media writing. She also contributed 
regularly to TV and radio, including appearances on BBC4’s ‘The 
Fantastical World of  Hormones’ and BBC Radio 4’s ‘Women’s Hour’. She 
was the scientific advisor on ‘Tide Tables’ a 2011 play supported by the 
Wellcome Trust and the Society for Endocrinology. The play centred on the 
challenges of  midlife as a time of  significant biological change.
SAFFRON WHITEHEAD
OBITUARY
‘Saffron was a dedicated advocate for 
women’s health and worked across the 
media to increase the public awareness 
of endocrine issues.’
‘Consistently gaining promotion 
while raising a family, Saffron was an 
important role model for younger female 
staff in the medical school, being one of 
only a small number of female professors 
at St George’s for most of her career.’
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Images by 
ENDOCRINOLOGISTS
Send us your best photos (high resolution please), along with either a reason why you like the shot or, if you prefer, simply a title 
for your photo, and your name and institution. Your image should be emailed to: endocrinologist@endocrinology.org. The Editorial 
Board will choose one or more images to publish inside the back cover of each issue of The Endocrinologist.
This issue’s photo was taken by Kenny Muir (Inverness). Kenny says ‘The image was taken in Glen Aric, Scotland, in January 2019.  
I had to take advantage of the full early morning cortisol peak to cope with the –12˚C temperature nadir!’
• Are you a keen photographer?
• Do you take photos with your smartphone?
If so, our feature ‘Images by endocrinologists’ is yet another reason to read  
The Endocrinologist.
©Kenny Muir

